Merit Medical Systems, Inc(NASDAQ:MMSI) 
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral inte...
Website: http://www.merit.com
Founded: 1987
Full Time Employees: 6,000
Sector: Healthcare
Industry: Medical Instruments & Supplies
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-12-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-12-31 | 2004-09-30 | 2004-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net sales | 384,157,000 | 382,462,000 | 355,351,000 | 355,158,000 | 339,845,000 | 338,003,000 | 323,508,000 | 324,515,000 | 315,230,000 | 320,056,000 | 297,565,000 | 293,415,000 | 287,175,000 | 294,976,000 | 275,415,000 | 278,492,000 | 267,021,000 | 280,325,000 | 248,913,000 | 258,004,000 | 243,975,000 | 218,371,000 | 243,525,000 | 257,922,000 | 243,049,000 | 255,532,000 | 238,349,000 | 233,249,000 | 221,659,000 | 224,810,000 | 203,035,000 | 190,897,000 | 179,337,000 | 186,549,000 | 171,069,000 | 157,715,000 | 156,975,000 | 151,071,000 | 138,077,000 | 138,404,000 | 136,086,000 | 138,082,000 | 129,577,000 | 132,780,000 | 128,808,000 | 128,865,000 | 119,236,000 | 120,016,000 | 115,210,000 | 109,875,000 | 103,948,000 | 102,231,000 | 95,907,000 | 91,092,000 | 90,477,000 | 91,249,000 | 86,631,000 | 81,203,000 | 73,172,000 | 74,948,000 | 67,432,000 | 66,759,000 | 64,837,000 | 58,371,000 | 57,996,000 | 58,153,000 | 57,441,000 | 53,553,000 | 38,356,250 | 50,584,000 | 51,811,000 | 51,030,000 | 50,816,000 | 46,697,000 | 48,121,000 | 45,040,000 | 42,682,000 | 41,224,000 | 42,405,000 | 40,274,000 | 39,339,000 | 35,476,000 | 38,920,944 |
yoy | 13.04% | 13.15% | 9.84% | 9.44% | 7.81% | 5.61% | 8.72% | 10.60% | 9.77% | 8.50% | 8.04% | 5.36% | 7.55% | 5.23% | 10.65% | 7.94% | 9.45% | 28.37% | 2.21% | 0.03% | 0.38% | -14.54% | 2.17% | 10.58% | 9.65% | 13.67% | 17.39% | 22.19% | 23.60% | 20.51% | 18.69% | 21.04% | 14.25% | 23.48% | 23.89% | 13.95% | 15.35% | 9.41% | 6.56% | 4.24% | 5.65% | 7.15% | 8.67% | 10.64% | 11.80% | 17.28% | 14.71% | 17.40% | 20.13% | 20.62% | 14.89% | 12.04% | 10.71% | 12.18% | 23.65% | 21.75% | 28.47% | 21.64% | 12.86% | 28.40% | 16.27% | 14.80% | 12.88% | 9.00% | 51.20% | 14.96% | 10.87% | 4.94% | -24.52% | 8.32% | 7.67% | 13.30% | 19.06% | 13.28% | 13.48% | 11.83% | 8.50% | 16.20% | 8.95% | ||||
qoq | 0.44% | 7.63% | 0.05% | 4.51% | 0.54% | 4.48% | -0.31% | 2.95% | -1.51% | 7.56% | 1.41% | 2.17% | -2.64% | 7.10% | -1.10% | 4.30% | -4.75% | 12.62% | -3.52% | 5.75% | 11.73% | -10.33% | -5.58% | 6.12% | -4.89% | 7.21% | 2.19% | 5.23% | -1.40% | 10.72% | 6.36% | 6.45% | -3.87% | 9.05% | 8.47% | 0.47% | 3.91% | 9.41% | -0.24% | 1.70% | -1.45% | 6.56% | -2.41% | 3.08% | -0.04% | 8.08% | -0.65% | 4.17% | 4.86% | 5.70% | 1.68% | 6.59% | 5.29% | 0.68% | -0.85% | 5.33% | 6.68% | 10.98% | -2.37% | 11.15% | 1.01% | 2.96% | 11.08% | 0.65% | -0.27% | 1.24% | 7.26% | 39.62% | -24.17% | -2.37% | 1.53% | 0.42% | 8.82% | -2.96% | 6.84% | 5.52% | 3.54% | -2.79% | 5.29% | 2.38% | 10.89% | -8.85% | |
cost of sales | 197,746,000 | 197,975,000 | 183,331,000 | 182,175,000 | 182,310,000 | 176,903,000 | 171,793,000 | 173,986,000 | 173,031,000 | 167,274,000 | 159,203,000 | 158,863,000 | 158,602,000 | 159,909,000 | 154,508,000 | 149,686,000 | 146,527,000 | 156,186,000 | 137,019,000 | 146,841,000 | 141,961,000 | 134,155,000 | 139,741,000 | 146,292,000 | 138,913,000 | 143,568,000 | 133,713,000 | 128,583,000 | 119,620,000 | 124,801,000 | 114,979,000 | 105,241,000 | 98,823,000 | 102,408,000 | 95,127,000 | 87,459,000 | 89,160,000 | 84,217,000 | 77,977,000 | 78,097,000 | 76,881,000 | 77,196,000 | 74,194,000 | 72,646,000 | 71,387,000 | 73,241,000 | 67,193,000 | 66,657,000 | 64,180,000 | 62,890,000 | 60,955,000 | 56,768,000 | 50,572,000 | 48,947,000 | 49,423,000 | 48,765,000 | 46,846,000 | 44,845,000 | 41,925,000 | 42,490,000 | 38,997,000 | 38,224,000 | 36,694,000 | 33,563,000 | 34,503,000 | 34,469,000 | 32,939,000 | 31,961,000 | 23,811,750 | 30,801,000 | 32,275,000 | 32,172,000 | 31,853,000 | 28,629,000 | 29,125,000 | 27,990,000 | 26,114,000 | 24,422,000 | 24,145,000 | 22,813,000 | 22,083,000 | 19,683,000 | 20,911,592 |
gross profit | 186,411,000 | 184,487,000 | 172,020,000 | 172,983,000 | 157,535,000 | 161,100,000 | 151,715,000 | 150,529,000 | 142,199,000 | 152,782,000 | 138,362,000 | 134,552,000 | 128,573,000 | 135,067,000 | 120,907,000 | 128,806,000 | 120,494,000 | 124,139,000 | 111,894,000 | 111,163,000 | 102,014,000 | 84,216,000 | 103,784,000 | 111,630,000 | 104,136,000 | 111,964,000 | 104,636,000 | 104,666,000 | 102,039,000 | 100,009,000 | 88,056,000 | 85,656,000 | 80,514,000 | 84,141,000 | 75,942,000 | 70,256,000 | 67,815,000 | 66,854,000 | 60,100,000 | 60,307,000 | 59,205,000 | 60,886,000 | 55,383,000 | 60,134,000 | 57,421,000 | 55,624,000 | 52,043,000 | 53,359,000 | 51,030,000 | 46,985,000 | 42,993,000 | 45,463,000 | 45,335,000 | 42,145,000 | 41,054,000 | 42,484,000 | 39,785,000 | 36,358,000 | 31,247,000 | 32,458,000 | 28,435,000 | 28,535,000 | 28,143,000 | 24,808,000 | 23,493,000 | 23,684,000 | 24,502,000 | 21,592,000 | -58,177,961.6 | 19,783,000 | 19,536,000 | 18,858,000 | 18,963,000 | 18,068,000 | 18,996,000 | 17,050,000 | 16,568,000 | 16,802,000 | 18,260,000 | 17,461,000 | 17,256,000 | 15,793,000 | 18,009,352 |
yoy | 18.33% | 14.52% | 13.38% | 14.92% | 10.78% | 5.44% | 9.65% | 11.87% | 10.60% | 13.12% | 14.44% | 4.46% | 6.70% | 8.80% | 8.05% | 15.87% | 18.12% | 47.41% | 7.81% | -0.42% | -2.04% | -24.78% | -0.81% | 6.65% | 2.06% | 11.95% | 18.83% | 22.19% | 26.73% | 18.86% | 15.95% | 21.92% | 18.73% | 25.86% | 26.36% | 16.50% | 14.54% | 9.80% | 8.52% | 0.29% | 3.11% | 9.46% | 6.42% | 12.70% | 12.52% | 18.39% | 21.05% | 17.37% | 12.56% | 11.48% | 4.72% | 7.01% | 13.95% | 15.92% | 31.39% | 30.89% | 39.92% | 27.42% | 11.03% | 30.84% | 21.04% | 20.48% | 14.86% | 14.89% | -140.38% | 19.72% | 25.42% | 14.50% | -406.80% | 9.49% | 2.84% | 10.60% | 14.46% | 7.53% | 4.03% | -2.35% | -3.99% | 6.39% | 1.39% | ||||
qoq | 1.04% | 7.25% | -0.56% | 9.81% | -2.21% | 6.19% | 0.79% | 5.86% | -6.93% | 10.42% | 2.83% | 4.65% | -4.81% | 11.71% | -6.13% | 6.90% | -2.94% | 10.94% | 0.66% | 8.97% | 21.13% | -18.85% | -7.03% | 7.20% | -6.99% | 7.00% | -0.03% | 2.57% | 2.03% | 13.57% | 2.80% | 6.39% | -4.31% | 10.80% | 8.09% | 3.60% | 1.44% | 11.24% | -0.34% | 1.86% | -2.76% | 9.94% | -7.90% | 4.72% | 3.23% | 6.88% | -2.47% | 4.56% | 8.61% | 9.29% | -5.43% | 0.28% | 7.57% | 2.66% | -3.37% | 6.78% | 9.43% | 16.36% | -3.73% | 14.15% | -0.35% | 1.39% | 13.44% | 5.60% | -0.81% | -3.34% | 13.48% | -137.11% | -394.08% | 1.26% | 3.60% | -0.55% | 4.95% | -4.89% | 11.41% | 2.91% | -1.39% | -7.98% | 4.58% | 1.19% | 9.26% | -12.31% | |
gross margin % | 48.52% | 48.24% | 48.41% | 48.71% | 46.35% | 47.66% | 46.90% | 46.39% | 45.11% | 47.74% | 46.50% | 45.86% | 44.77% | 45.79% | 43.90% | 46.25% | 45.13% | 44.28% | 44.95% | 43.09% | 41.81% | 38.57% | 42.62% | 43.28% | 42.85% | 43.82% | 43.90% | 44.87% | 46.03% | 44.49% | 43.37% | 44.87% | 44.90% | 45.10% | 44.39% | 44.55% | 43.20% | 44.25% | 43.53% | 43.57% | 43.51% | 44.09% | 42.74% | 45.29% | 44.58% | 43.16% | 43.65% | 44.46% | 44.29% | 42.76% | 41.36% | 44.47% | 47.27% | 46.27% | 45.38% | 46.56% | 45.92% | 44.77% | 42.70% | 43.31% | 42.17% | 42.74% | 43.41% | 42.50% | 40.51% | 40.73% | 42.66% | 40.32% | -151.68% | 39.11% | 37.71% | 36.95% | 37.32% | 38.69% | 39.48% | 37.86% | 38.82% | 40.76% | 43.06% | 43.36% | 43.86% | 44.52% | 46.27% |
operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
selling, general and administrative | 119,801,000 | 113,097,000 | 107,486,000 | 111,074,000 | 99,644,000 | 94,585,000 | 94,428,000 | 95,751,000 | 86,854,000 | 100,927,000 | 90,144,000 | 83,243,000 | 89,780,000 | 85,487,000 | 84,015,000 | 76,629,000 | 86,474,000 | 91,563,000 | 81,024,000 | 79,934,000 | 72,215,000 | 66,767,000 | 78,808,000 | 82,091,000 | 86,936,000 | 79,977,000 | 78,270,000 | 75,629,000 | 66,382,000 | 69,095,000 | 64,913,000 | 59,238,000 | 54,716,000 | 57,409,000 | 57,771,000 | 45,842,000 | 53,198,000 | 43,653,000 | 41,704,000 | 24,591,000 | 19,032,000 | ||||||||||||||||||||||||||||||||||||||||||
research and development | 23,966,000 | 24,367,000 | 22,478,000 | 25,194,000 | 20,527,000 | 20,263,000 | 21,482,000 | 21,639,000 | 19,646,000 | 20,129,000 | 21,314,000 | 20,436,000 | 19,221,000 | 18,466,000 | 17,387,000 | 20,406,000 | 16,974,000 | 17,593,000 | 16,274,000 | 15,133,000 | 13,506,000 | 14,026,000 | 14,872,000 | 16,254,000 | 16,987,000 | 16,332,000 | 16,043,000 | 15,369,000 | 14,525,000 | 15,316,000 | 14,322,000 | 12,727,000 | 12,838,000 | 13,313,000 | 12,525,000 | 11,789,000 | 11,424,000 | 11,529,000 | 10,588,000 | 11,421,000 | 10,515,000 | 9,202,000 | 9,672,000 | 9,523,000 | 8,688,000 | 9,641,000 | 8,780,000 | 8,822,000 | 7,308,000 | 8,648,000 | 9,108,000 | 7,665,000 | 7,098,000 | 6,091,000 | 5,401,000 | 5,462,000 | 4,984,000 | 4,671,000 | 3,865,000 | 3,742,000 | 3,057,000 | 3,292,000 | 2,893,000 | 2,079,000 | 2,404,000 | 2,186,000 | 2,654,000 | 1,916,000 | 1,640,250 | 1,990,000 | 2,207,000 | 2,364,000 | 2,361,000 | 2,119,000 | 2,023,000 | 2,078,000 | 1,910,000 | 1,788,000 | 1,747,000 | 1,547,000 | 1,405,000 | 1,210,000 | 1,273,344 |
contingent consideration expense | 32,000 | 143,000 | 1,023,000 | 151,000 | 103,000 | 306,000 | -117,000 | -473,000 | 562,000 | 1,094,000 | 521,000 | -91,000 | 915,000 | 1,187,000 | 2,600,000 | -161,000 | 1,115,000 | 1,805,000 | 402,000 | 221,000 | -4,356,000 | 343,000 | 4,897,000 | 893,250 | 392,000 | 2,406,000 | 775,000 | -256,000 | -661,000 | 178,000 | 40,000 | -337,000 | 20,000 | -18,000 | 37,000 | -38,000 | -94,000 | 91,000 | 102,000 | 121,000 | 122,000 | ||||||||||||||||||||||||||||||||||||||||||
total operating expenses | 143,799,000 | 137,607,000 | 130,987,000 | 136,419,000 | 120,274,000 | 115,154,000 | 115,793,000 | 116,917,000 | 107,062,000 | 123,970,000 | 111,979,000 | 104,135,000 | 109,916,000 | 111,811,000 | 105,674,000 | 106,910,000 | 104,563,000 | 115,244,000 | 97,700,000 | 95,156,000 | 101,950,000 | 103,211,000 | 102,422,000 | 115,040,000 | 107,017,000 | 99,763,000 | 95,113,000 | 91,004,000 | 80,978,000 | 84,895,000 | 79,275,000 | 72,437,000 | 79,635,000 | 70,779,000 | 70,333,000 | 57,654,000 | 64,828,000 | 55,273,000 | 52,394,000 | 52,257,000 | 50,658,000 | 48,644,000 | 46,679,000 | 45,917,000 | 45,345,000 | 48,240,000 | 45,554,000 | 42,443,000 | 42,639,000 | 40,205,000 | 41,236,000 | 41,133,000 | 36,253,000 | 36,519,000 | 34,547,000 | 31,637,000 | 29,575,000 | 30,835,000 | 34,689,000 | 23,681,000 | 22,089,000 | 20,072,000 | 19,180,000 | 16,908,000 | 15,291,000 | 16,515,000 | 15,493,000 | 14,988,000 | 10,535,250 | 13,697,000 | 14,065,000 | 14,379,000 | 14,270,000 | 12,932,000 | 13,520,000 | 13,316,000 | 11,446,000 | 11,798,000 | 11,073,000 | 11,254,000 | 10,687,000 | 9,667,000 | 10,068,969 |
income from operations | 42,612,000 | 46,880,000 | 41,033,000 | 36,564,000 | 37,261,000 | 45,946,000 | 35,922,000 | 33,612,000 | 35,137,000 | 28,812,000 | 26,383,000 | 30,417,000 | 18,657,000 | 23,256,000 | 15,233,000 | 21,896,000 | 15,931,000 | 8,895,000 | 14,194,000 | 16,007,000 | 64,000 | -18,995,000 | 1,362,000 | -3,410,000 | -2,881,000 | 12,201,000 | 9,523,000 | 13,662,000 | 21,061,000 | 15,114,000 | 8,781,000 | 13,219,000 | 879,000 | 13,362,000 | 5,609,000 | 12,602,000 | 2,987,000 | 11,581,000 | 7,706,000 | 8,050,000 | 8,547,000 | 12,242,000 | 8,704,000 | 14,217,000 | 12,076,000 | 7,384,000 | 6,489,000 | 10,916,000 | 8,391,000 | 6,780,000 | 1,757,000 | 4,330,000 | 9,082,000 | 5,626,000 | 6,507,000 | 10,847,000 | 10,210,000 | 5,523,000 | 8,777,000 | 6,346,000 | 8,463,000 | 8,963,000 | 7,900,000 | 8,202,000 | 7,169,000 | 9,009,000 | 6,604,000 | -16,036,988.9 | 6,086,000 | 5,471,000 | 4,479,000 | 4,693,000 | 5,136,000 | 5,476,000 | 3,734,000 | 5,122,000 | 5,004,000 | 7,187,000 | 6,207,000 | 6,569,000 | 6,126,000 | 7,940,383 | |
yoy | 14.36% | 2.03% | 14.23% | 8.78% | 6.04% | 59.47% | 36.16% | 10.50% | 88.33% | 23.89% | 73.20% | 38.92% | 17.11% | 161.45% | 7.32% | 36.79% | 24792.19% | -146.83% | 942.14% | -569.41% | -102.22% | -255.68% | -85.70% | -124.96% | -113.68% | -19.27% | 8.45% | 3.35% | 2296.02% | 13.11% | 56.55% | 4.90% | -70.57% | 15.38% | -27.21% | 56.55% | -65.05% | -5.40% | -11.47% | -43.38% | -29.22% | 65.79% | 34.13% | 30.24% | 43.92% | 8.91% | 269.32% | 152.10% | -7.61% | 20.51% | -73.00% | -60.08% | -11.05% | 1.86% | 23.58% | 60.89% | -34.74% | 11.10% | -22.63% | 18.05% | -0.51% | 19.62% | -151.14% | 17.79% | 64.67% | 47.44% | -441.72% | 18.50% | -0.09% | 19.95% | -8.38% | 2.64% | -23.81% | -39.84% | -22.03% | -18.32% | -9.49% | ||||||
qoq | -9.10% | 14.25% | 12.22% | -1.87% | -18.90% | 27.90% | 6.87% | -4.34% | 21.95% | 9.21% | -13.26% | 63.03% | -19.78% | 52.67% | -30.43% | 37.44% | 79.10% | -37.33% | -11.33% | 24910.94% | -100.34% | -1494.64% | -139.94% | 18.36% | -123.61% | 28.12% | -30.30% | -35.13% | 39.35% | 72.12% | -33.57% | 1403.87% | -93.42% | 138.22% | -55.49% | 321.89% | -74.21% | 50.29% | -4.27% | -5.81% | -30.18% | 40.65% | -38.78% | 17.73% | 63.54% | 13.79% | -40.56% | 30.09% | 23.76% | 285.89% | -59.42% | -52.32% | 61.43% | -13.54% | -40.01% | 6.24% | 84.86% | 38.31% | -25.01% | -5.58% | 13.46% | -3.68% | 14.41% | -20.42% | 36.42% | -141.18% | -363.51% | 11.24% | 22.15% | -4.56% | -8.63% | -6.21% | 46.65% | -27.10% | 2.36% | -30.37% | 15.79% | -5.51% | 7.23% | -22.85% | |||
operating margin % | 11.09% | 12.26% | 11.55% | 10.30% | 10.96% | 13.59% | 11.10% | 10.36% | 11.15% | 9.00% | 8.87% | 10.37% | 6.50% | 7.88% | 5.53% | 7.86% | 5.97% | 3.17% | 5.70% | 6.20% | 0.03% | -8.70% | 0.56% | -1.32% | -1.19% | 4.77% | 4.00% | 5.86% | 9.50% | 6.72% | 4.32% | 6.92% | 0.49% | 7.16% | 3.28% | 7.99% | 1.90% | 7.67% | 5.58% | 5.82% | 6.28% | 8.87% | 6.72% | 10.71% | 9.38% | 5.73% | 5.44% | 9.10% | 7.28% | 6.17% | 1.69% | 4.24% | 9.47% | 6.18% | 7.19% | 11.89% | 11.79% | 6.80% | 0% | 11.71% | 9.41% | 12.68% | 13.82% | 13.53% | 14.14% | 12.33% | 15.68% | 12.33% | -41.81% | 12.03% | 10.56% | 8.78% | 9.24% | 11.00% | 11.38% | 8.29% | 12.00% | 12.14% | 16.95% | 15.41% | 16.70% | 17.27% | 20.40% |
other income: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 3,615,000 | 3,761,000 | 3,790,000 | 4,741,000 | 6,652,000 | 7,561,000 | 7,276,000 | 1,923,000 | 181,000 | 221,000 | 131,000 | 123,000 | 116,000 | 96,000 | 104,000 | 101,000 | 104,000 | 92,000 | 472,000 | 370,000 | 67,000 | 88,000 | 79,000 | -1,318,000 | 328,000 | 342,000 | 357,000 | 352,000 | 359,000 | 342,000 | 146,000 | 115,000 | 94,000 | 89,000 | 83,000 | 26,000 | 29,000 | 16,000 | 9,000 | 62,000 | 78,000 | 79,000 | 53,000 | 30,000 | 41,000 | 79,000 | 67,000 | 55,000 | 69,000 | 74,000 | 57,000 | 50,000 | 57,000 | 77,000 | 36,000 | 14,000 | 2,000 | 7,000 | 7,000 | 12,000 | 8,000 | 14,000 | 28,000 | 122,000 | 286,000 | 183,000 | 162,000 | 150,000 | 62,000 | 96,000 | 63,000 | 89,000 | 71,000 | 69,000 | 64,000 | 46,000 | 67,000 | 99,000 | 143,000 | 182,000 | 157,000 | 143,000 | 133,330 |
interest expense | -6,754,000 | -6,775,000 | -6,568,000 | -7,993,000 | -7,501,000 | -7,679,000 | -8,046,000 | -4,977,000 | -4,841,000 | -3,682,000 | -2,011,000 | -2,159,000 | -1,831,000 | -1,348,000 | -1,002,000 | -1,105,000 | -1,233,000 | -1,386,000 | -1,537,000 | -1,938,000 | -2,197,000 | -2,715,000 | -3,144,000 | -3,118,000 | -3,415,000 | -3,115,000 | -2,764,000 | -2,296,000 | -2,329,000 | -3,338,000 | -2,398,000 | -1,801,000 | -1,590,000 | -1,639,000 | -2,706,000 | -2,678,000 | -3,022,000 | -1,768,000 | -1,329,000 | -1,453,000 | -1,489,000 | -1,713,000 | -1,574,000 | -2,747,000 | -1,916,000 | -1,842,000 | -1,539,000 | -252,000 | -128,000 | -34,000 | -19,000 | ||||||||||||||||||||||||||||||||
other income — net | -933,000 | -487,000 | -167,000 | 245,000 | 15,000 | -804,000 | 909,000 | -255,000 | -451,000 | 997,000 | 1,774,000 | 660,000 | -1,452,000 | -1,676,000 | -3,549,000 | -2,422,000 | 3,188,000 | -810,000 | 170,000 | 264,000 | -328,000 | 1,000 | 33,000 | -480,000 | -105,000 | -476,000 | -85,000 | 280,000 | -34,000 | 144,000 | -2,603,000 | 5,055,000 | -1,951,000 | -1,775,000 | -1,545,000 | -2,480,000 | -45,000 | ||||||||||||||||||||||||||||||||||||||||||||||
total other expense — net | -4,072,000 | -3,501,000 | -3,075,000 | -3,419,000 | -604,000 | -103,000 | -1,574,000 | -2,145,000 | -4,915,000 | -3,912,000 | -883,000 | -262,000 | -1,055,000 | -2,555,000 | -1,062,000 | -1,715,000 | -1,754,000 | -2,030,000 | -1,500,000 | -2,762,000 | -2,248,000 | -3,305,000 | -3,354,000 | -2,172,250 | -2,809,000 | -3,202,000 | -2,677,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before income taxes | 38,540,000 | 43,379,000 | 37,958,000 | 33,145,000 | 36,657,000 | 45,843,000 | 34,348,000 | 31,467,000 | 30,222,000 | 24,900,000 | 25,500,000 | 30,155,000 | 17,602,000 | 20,701,000 | 14,171,000 | 20,181,000 | 14,177,000 | 6,865,000 | 12,694,000 | 13,245,000 | -2,184,000 | -22,300,000 | -1,992,000 | -7,962,000 | -5,690,000 | 8,999,000 | 6,846,000 | 12,210,000 | 19,385,000 | 11,565,000 | 6,359,000 | 11,280,000 | -2,205,000 | 11,313,000 | 15,493,000 | 9,622,000 | -5,000 | 9,862,000 | 5,906,000 | 6,554,000 | 6,660,000 | 10,523,000 | 7,463,000 | 12,351,000 | 10,253,000 | 5,082,000 | 3,886,000 | 8,182,000 | 6,440,000 | 5,005,000 | 212,000 | 1,850,000 | 9,037,000 | 5,776,000 | 6,683,000 | 10,618,000 | 9,798,000 | 5,131,000 | 8,839,000 | 6,330,000 | 8,434,000 | 8,985,000 | 8,074,000 | 8,543,000 | 7,398,000 | 9,155,000 | 6,749,000 | 4,071,750 | 6,186,000 | 5,533,000 | 4,567,000 | 4,733,000 | 5,225,000 | 5,473,000 | 3,752,000 | 5,131,000 | 5,090,000 | 7,310,000 | 6,368,000 | 6,785,000 | 6,229,000 | 8,080,354 | |
income tax expense | 10,785,000 | 10,798,000 | 7,811,000 | 5,198,000 | 8,213,000 | 10,117,000 | 6,108,000 | 3,838,000 | 4,388,000 | 4,655,000 | 4,797,000 | -3,246,000 | 2,330,000 | 5,403,000 | 3,626,000 | -432,000 | 2,210,000 | 1,949,000 | 1,736,000 | -2,133,000 | 825,000 | -3,242,000 | 1,162,000 | -3,757,000 | -2,292,000 | 2,140,000 | 651,000 | 3,021,000 | 2,766,000 | 624,000 | 1,090,000 | 4,474,000 | 1,364,000 | 1,830,000 | 690,000 | 2,116,000 | -978,000 | 2,572,000 | 1,555,000 | 145,000 | 1,842,000 | 3,122,000 | 2,289,000 | 3,680,000 | 2,489,000 | 1,366,000 | 1,642,000 | 833,000 | 1,253,000 | 1,209,000 | 1,811,000 | 3,746,000 | 3,159,000 | 3,124,000 | 1,822,000 | 2,349,000 | 3,144,000 | 2,537,000 | 3,151,000 | 2,198,000 | 3,337,000 | 2,432,000 | 1,356,750 | 1,891,000 | 1,937,000 | 1,598,000 | 1,680,000 | 1,900,000 | 1,951,000 | 1,351,000 | 1,436,000 | 1,763,000 | 2,629,000 | 2,294,000 | 1,896,500 | 2,040,000 | 3,008,696 | ||||||
net income | 27,755,000 | 32,581,000 | 30,147,000 | 27,947,000 | 28,444,000 | 35,726,000 | 28,240,000 | 27,629,000 | 25,834,000 | 20,245,000 | 20,703,000 | 33,401,000 | 15,272,000 | 15,298,000 | 10,545,000 | 20,613,000 | 11,967,000 | 4,916,000 | 10,958,000 | 15,378,000 | -3,009,000 | -19,058,000 | -3,154,000 | -4,205,000 | -3,398,000 | 6,859,000 | 6,195,000 | 9,189,000 | 16,619,000 | 10,941,000 | 5,269,000 | 6,806,000 | -3,569,000 | 9,483,000 | 14,803,000 | 7,506,000 | 973,000 | 7,290,000 | 4,351,000 | 6,409,000 | 4,818,000 | 7,401,000 | 5,174,000 | 8,671,000 | 7,764,000 | 3,716,000 | 2,823,000 | 6,540,000 | 5,607,000 | 3,752,000 | 671,000 | 641,000 | 7,226,000 | 4,970,000 | 4,563,000 | 6,872,000 | 6,639,000 | 4,210,000 | -1,973,000 | 5,715,000 | 4,508,000 | 6,085,000 | 5,841,000 | 5,537,000 | 5,392,000 | 5,200,000 | 5,818,000 | 4,317,000 | -10,859,992.5 | 4,295,000 | 3,596,000 | 2,969,000 | 3,053,000 | 3,325,000 | 3,522,000 | 2,401,000 | 3,695,000 | 3,327,000 | 4,681,000 | 4,074,000 | 4,297,000 | 4,189,000 | 5,071,658 |
yoy | -2.42% | -8.80% | 6.75% | 1.15% | 10.10% | 76.47% | 36.41% | -17.28% | 69.16% | 32.34% | 96.33% | 62.04% | 27.62% | 211.19% | -3.77% | 34.04% | -497.71% | -125.79% | -447.43% | -465.71% | -11.45% | -377.85% | -150.91% | -145.76% | -120.45% | -37.31% | 17.57% | 35.01% | -565.65% | 15.37% | -64.41% | -9.33% | -466.80% | 30.08% | 240.22% | 17.12% | -79.80% | -1.50% | -15.91% | -26.09% | -37.94% | 99.17% | 83.28% | 32.58% | 38.47% | -0.96% | 320.72% | 920.28% | -22.41% | -24.51% | -85.29% | -90.67% | 8.84% | 18.05% | -331.27% | 20.24% | 47.27% | -30.81% | -133.78% | 3.21% | -16.39% | 17.02% | 0.40% | 28.26% | -149.65% | 21.07% | 61.79% | 45.40% | -455.72% | 29.17% | 2.10% | 23.66% | -17.37% | -0.06% | -24.76% | -41.07% | -14.01% | -20.58% | -7.70% | ||||
qoq | -14.81% | 8.07% | 7.87% | -1.75% | -20.38% | 26.51% | 2.21% | 6.95% | 27.61% | -2.21% | -38.02% | 118.71% | -0.17% | 45.07% | -48.84% | 72.25% | 143.43% | -55.14% | -28.74% | -611.07% | -84.21% | 504.25% | -24.99% | 23.75% | -149.54% | 10.72% | -32.58% | -44.71% | 51.90% | 107.65% | -22.58% | -290.70% | -137.64% | -35.94% | 97.22% | 671.43% | -86.65% | 67.55% | -32.11% | 33.02% | -34.90% | 43.04% | -40.33% | 11.68% | 108.93% | 31.63% | -56.83% | 16.64% | 49.44% | 459.17% | 4.68% | -91.13% | 45.39% | 8.92% | -33.60% | 3.51% | 57.70% | -313.38% | -134.52% | 26.77% | -25.92% | 4.18% | 5.49% | 2.69% | 3.69% | -10.62% | 34.77% | -139.75% | -352.85% | 19.44% | 21.12% | -2.75% | -8.18% | -5.59% | 46.69% | -35.02% | 11.06% | -28.93% | 14.90% | -5.19% | 2.58% | -17.40% | |
net income margin % | 7.22% | 8.52% | 8.48% | 7.87% | 8.37% | 10.57% | 8.73% | 8.51% | 8.20% | 6.33% | 6.96% | 11.38% | 5.32% | 5.19% | 3.83% | 7.40% | 4.48% | 1.75% | 4.40% | 5.96% | -1.23% | -8.73% | -1.30% | -1.63% | -1.40% | 2.68% | 2.60% | 3.94% | 7.50% | 4.87% | 2.60% | 3.57% | -1.99% | 5.08% | 8.65% | 4.76% | 0.62% | 4.83% | 3.15% | 4.63% | 3.54% | 5.36% | 3.99% | 6.53% | 6.03% | 2.88% | 2.37% | 5.45% | 4.87% | 3.41% | 0.65% | 0.63% | 7.53% | 5.46% | 5.04% | 7.53% | 7.66% | 5.18% | -2.70% | 7.63% | 6.69% | 9.11% | 9.01% | 9.49% | 9.30% | 8.94% | 10.13% | 8.06% | -28.31% | 8.49% | 6.94% | 5.82% | 6.01% | 7.12% | 7.32% | 5.33% | 8.66% | 8.07% | 11.04% | 10.12% | 10.92% | 11.81% | 13.03% |
earnings per common share | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 470 | 550 | 510 | 480 | 490 | 610 | 490 | 480 | 450 | 350 | 360 | 580 | 270 | 270 | 190 | 360 | 210 | 90 | 200 | 280 | -50 | -340 | -60 | -80 | -60 | 120 | 110 | 160 | 310 | 220 | 100 | 130 | -70 | 190 | 330 | 170 | 20 | 160 | 100 | 140 | 110 | 170 | 120 | 200 | 180 | 90 | 70 | 150 | 130 | 90 | 20 | 20 | 170 | 120 | 110 | 190 | 190 | 150 | -70 | 200 | 160 | 220 | 210 | 200 | 137.5 | 190 | 210 | 160 | 100 | 160 | 130 | 110 | 85 | 120 | 130 | 90 | 112.5 | 120 | 180 | 150 | 130 | 160 | 0.19 |
diluted | 460 | 540 | 490 | 460 | 480 | 610 | 480 | 480 | 440 | 350 | 360 | 580 | 270 | 270 | 180 | 350 | 210 | 90 | 190 | 280 | -50 | -340 | -60 | -70 | -60 | 120 | 110 | 160 | 300 | 210 | 100 | 130 | -70 | 190 | 320 | 170 | 20 | 160 | 100 | 140 | 110 | 170 | 120 | 200 | 180 | 90 | 70 | 160 | 130 | 90 | 20 | 10 | 170 | 110 | 110 | 180 | 180 | 140 | -70 | 200 | 160 | 210 | 210 | 190 | 135 | 180 | 210 | 150 | 95 | 150 | 130 | 100 | 82.5 | 120 | 130 | 90 | 107.5 | 120 | 170 | 150 | 122.5 | 150 | 0.18 |
weighted-average shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 59,245,000 | 59,140,000 | 58,897,000 | 58,218,000 | 58,231,000 | 58,139,000 | 57,958,000 | 57,593,000 | 57,682,000 | 57,537,000 | 57,352,000 | 56,806,000 | 56,835,000 | 56,691,000 | 56,593,000 | 56,145,000 | 56,302,000 | 56,061,000 | 55,717,000 | 55,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 59,919,000 | 60,611,000 | 61,278,000 | 59,365,000 | 59,537,000 | 58,740,000 | 58,567,000 | 58,356,000 | 58,375,000 | 58,473,000 | 58,183,000 | 57,671,000 | 57,586,000 | 57,600,000 | 57,531,000 | 57,359,000 | 57,549,000 | 57,277,000 | 56,978,000 | 55,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other expense — net | -297,000 | -1,303,000 | -164,000 | -711,000 | -625,000 | -736,000 | -435,000 | -2,980,000 | -2,992,000 | -1,719,000 | -1,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment charges | 270,000 | 547,000 | 1,672,000 | 4,283,000 | 8,199,000 | 20,585,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | 1,550,000 | 6,671,000 | 500,000 | 25,000 | 262,000 | 75,000 | 306,000 | 12,061,000 | 75,000 | 61,000 | 300,000 | 1,000,000 | 275,000 | 2,400,000 | 3,438,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
legal settlement | 484,000 | 18,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per common share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 470 | 550 | 510 | 480 | 490 | 610 | 490 | 480 | 450 | 350 | 360 | 580 | 270 | 270 | 190 | 360 | 210 | 90 | 200 | 280 | -50 | -340 | -60 | -80 | -60 | 120 | 110 | 160 | 310 | 220 | 100 | 130 | -70 | 190 | 330 | 170 | 20 | 160 | 100 | 140 | 110 | 170 | 120 | 200 | 180 | 90 | 70 | 150 | 130 | 90 | 20 | 20 | 170 | 120 | 110 | 190 | 190 | 150 | -70 | 200 | 160 | 220 | 210 | 200 | 137.5 | 190 | 210 | 160 | 100 | 160 | 130 | 110 | 85 | 120 | 130 | 90 | 112.5 | 120 | 180 | 150 | 130 | 160 | 0.19 |
diluted | 460 | 540 | 490 | 460 | 480 | 610 | 480 | 480 | 440 | 350 | 360 | 580 | 270 | 270 | 180 | 350 | 210 | 90 | 190 | 280 | -50 | -340 | -60 | -70 | -60 | 120 | 110 | 160 | 300 | 210 | 100 | 130 | -70 | 190 | 320 | 170 | 20 | 160 | 100 | 140 | 110 | 170 | 120 | 200 | 180 | 90 | 70 | 160 | 130 | 90 | 20 | 10 | 170 | 110 | 110 | 180 | 180 | 140 | -70 | 200 | 160 | 210 | 210 | 190 | 135 | 180 | 210 | 150 | 95 | 150 | 130 | 100 | 82.5 | 120 | 130 | 90 | 107.5 | 120 | 170 | 150 | 122.5 | 150 | 0.18 |
weighted-average shares outstanding: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 59,245,000 | 59,140,000 | 58,897,000 | 58,218,000 | 58,231,000 | 58,139,000 | 57,958,000 | 57,593,000 | 57,682,000 | 57,537,000 | 57,352,000 | 56,806,000 | 56,835,000 | 56,691,000 | 56,593,000 | 56,145,000 | 56,302,000 | 56,061,000 | 55,717,000 | 55,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 59,919,000 | 60,611,000 | 61,278,000 | 59,365,000 | 59,537,000 | 58,740,000 | 58,567,000 | 58,356,000 | 58,375,000 | 58,473,000 | 58,183,000 | 57,671,000 | 57,586,000 | 57,600,000 | 57,531,000 | 57,359,000 | 57,549,000 | 57,277,000 | 56,978,000 | 55,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income - net | -1,194,000 | -118,000 | -116,000 | 278,000 | 492,000 | 294,000 | -553,000 | -170,000 | 59,500 | 159,000 | 68,000 | 23,500 | 18,000 | 62,000 | 22,000 | 174,000 | 6,250 | 46,000 | 146,000 | 145,000 | 62,500 | 100,000 | 62,000 | 88,000 | 18,000 | 92,500 | 86,000 | 123,000 | 161,000 | 112,500 | 103,000 | 139,971 | |||||||||||||||||||||||||||||||||||||||||||||||||||
average common shares: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 13,846,500 | 55,505,000 | 55,406,000 | 55,246,000 | 46,000 | 55,152,000 | 55,017,000 | 54,917,000 | 834,000 | 53,431,000 | 50,473,000 | 50,277,000 | 473,000 | 50,150,000 | 49,957,000 | 44,830,000 | 62,000 | 44,447,000 | 44,308,000 | 44,275,000 | 60,000 | 44,165,000 | 44,055,000 | 43,703,000 | 90,000 | 43,229,000 | 43,061,000 | 42,865,000 | 47,000 | 42,596,000 | 42,562,000 | 42,520,000 | 89,000 | 42,202,000 | 963,000 | 41,909,000 | 36,804,000 | 35,593,000 | 33,000 | 28,234,000 | 28,194,000 | 28,181,000 | 27,970,000 | 27,924,000 | 28,057,000 | 6,917,250 | 27,900,000 | 27,603,000 | 27,495,000 | 6,863,250 | 27,327,000 | 27,727,000 | 27,653,000 | 6,818,468,250 | 27,363,182,000 | 27,260,928,000 | 27,195,671,000 | 6,687,239,250 | 27,008,936,000 | 26,725,684,000 | 26,506,733,000 | 6,562,303,000 | 26,380,059,000 | 26,301,004 | |||||||||||||||||||
diluted | 13,846,500 | 55,505,000 | 55,406,000 | 55,246,000 | -158,000 | 55,152,000 | 56,555,000 | 56,490,000 | 835,000 | 55,103,000 | 52,154,000 | 51,910,000 | 546,000 | 51,599,000 | 51,188,000 | 45,820,000 | 99,000 | 45,000,000 | 44,703,000 | 44,579,000 | 44,000 | 44,734,000 | 44,517,000 | 44,145,000 | 94,000 | 43,398,000 | 43,310,000 | 43,234,000 | 91,000 | 42,872,000 | 42,670,000 | 42,835,000 | 74,000 | 42,692,000 | 901,000 | 42,502,000 | 37,677,000 | 36,254,000 | 18,000 | 28,234,000 | 28,729,000 | 28,758,000 | 28,690,000 | 28,427,000 | 28,547,000 | 7,120,500 | 28,812,000 | 28,325,000 | 28,301,000 | 7,065,000 | 28,031,000 | 28,480,000 | 28,617,000 | 7,028,966,250 | 28,286,928,000 | 27,966,729,000 | 28,092,099,000 | 6,952,763,250 | 28,112,012,000 | 27,726,579,000 | 27,598,050,000 | 6,939,206,500 | 27,760,219,000 | 27,729,654 | |||||||||||||||||||
impairment and other charges | 3,875,000 | 3,845,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other expense - net | -678,000 | -289,000 | -429,000 | -270,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible asset impairment charge | 812,500 | 2,702,000 | 548,000 | 164,250 | 657,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
see condensed notes to consolidated financial statements. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on bargain purchase | 243,000 | -778,000 | -669,000 | 12,243,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
selling, general, and administrative | 28,851,750 | 39,201,000 | 39,321,000 | 36,885,000 | 36,212,000 | 36,328,000 | 38,599,000 | 36,774,000 | 33,640,000 | 31,350,000 | 31,557,000 | 32,128,000 | 33,468,000 | 28,880,000 | 28,028,000 | 25,708,000 | 26,175,000 | 26,164,000 | 22,480,000 | 19,939,000 | 16,780,000 | 16,287,000 | 14,829,000 | 10,060,000 | 14,329,000 | 12,839,000 | 13,072,000 | 8,895,000 | 11,707,000 | 11,858,000 | 12,015,000 | 8,394,250 | 10,813,000 | 11,301,000 | 11,238,000 | 7,260,750 | 10,010,000 | 9,326,000 | 9,707,000 | 6,447,250 | 8,457,000 | 8,795,625 | |||||||||||||||||||||||||||||||||||||||||
intangible asset impairment charges | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contingent consideration (benefit) expense | 46,250 | -58,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other (expense) — net | -1,211,750 | -1,887,000 | -1,719,000 | -1,241,000 | -1,682,000 | -1,823,000 | -28,000 | -64,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets impairment charge | 275,500 | 1,102,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contingent consideration benefit | 182,000 | -773,000 | -19,000 | -4,108,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | -1,741,750 | -2,008,000 | -2,353,000 | -2,606,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax benefit | 1,063,000 | -459,000 | 2,256,250 | 2,120,000 | 851,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets impairment charges | 2,022,250 | 8,089,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income | -43,500 | -104,000 | -7,000 | -63,000 | -2,278,000 | 26,000 | 11,000 | 50,000 | 52,000 | 500 | 4,000 | 20,000 | 6,641 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill impairment charge | 8,344,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other income - net | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income net | 33,500 | 89,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment | 196,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
litigation settlement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
miscellaneouse expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other operating income: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of land | 1,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2011-12-31 | 2011-09-30 | 2011-03-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-09-30 | 2004-06-30 | 2004-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 392,457,000 | 341,819,000 | 395,529,000 | 376,715,000 | 523,128,000 | 636,658,000 | 581,921,000 | 587,036,000 | 58,673,000 | 72,084,000 | 57,945,000 | 58,408,000 | 51,481,000 | 63,003,000 | 53,875,000 | 67,750,000 | 68,904,000 | 69,672,000 | 58,519,000 | 56,916,000 | 44,551,000 | 49,702,000 | 50,080,000 | 44,320,000 | 37,315,000 | 35,182,000 | 49,522,000 | 67,359,000 | 51,955,000 | 43,512,000 | 34,171,000 | 32,336,000 | 23,362,000 | 37,675,000 | 26,464,000 | 19,171,000 | 17,318,000 | 10,487,000 | 5,162,000 | 4,177,000 | 5,819,000 | 3,465,000 | 5,298,000 | 4,254,000 | 5,992,000 | 5,763,000 | 4,873,000 | 16,430,000 | 31,081,000 | 26,756,000 | 23,757,000 | 12,199,000 | 9,281,000 | 9,645,000 | 7,005,000 | 7,644,000 | 9,014,000 | 11,976,000 | 18,835,000 | 28,617,000 | 34,434,000 | 35,865,142 | ||||||||||||||||
trade receivables — net of allowance for credit losses — 2025 — 10,113 and 2024 — 9,729 | 210,292,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other receivables | 19,062,000 | 14,292,000 | 17,116,000 | 16,588,000 | 15,325,000 | 10,612,000 | 10,980,000 | 10,517,000 | 13,576,000 | 12,634,000 | 14,559,000 | 12,992,000 | 10,827,000 | 10,627,000 | 11,748,000 | 17,763,000 | 10,659,000 | 8,376,000 | 8,719,000 | 7,774,000 | 8,073,000 | 8,214,000 | 9,246,000 | 10,016,000 | 11,751,000 | 11,520,000 | 10,694,000 | 11,879,000 | 8,903,000 | 8,490,000 | 8,727,000 | 9,429,000 | 5,900,000 | 5,560,000 | 4,902,000 | 5,445,000 | 3,350,000 | 4,742,000 | 5,501,000 | 6,799,000 | -735,000 | -3,042,000 | -885,000 | -753,000 | 439,000 | -609,000 | -463,000 | -586,000 | -760,000 | -490,000 | -245,000 | 1,442,000 | 1,267,000 | 1,641,000 | 447,000 | 644,000 | 465,000 | 460,000 | 711,000 | 706,000 | 800,000 | 929,000 | 882,000 | 734,000 | 457,000 | 293,000 | 553,000 | 252,000 | 270,000 | 253,000 | ||||||||
inventories | 326,550,000 | 323,309,000 | 317,936,000 | 306,063,000 | 310,527,000 | 298,224,000 | 302,733,000 | 303,871,000 | 303,923,000 | 305,943,000 | 289,581,000 | 265,991,000 | 246,660,000 | 233,154,000 | 231,451,000 | 221,922,000 | 208,081,000 | 194,524,000 | 200,308,000 | 198,019,000 | 209,109,000 | 221,417,000 | 227,776,000 | 225,698,000 | 216,766,000 | 202,994,000 | 198,922,000 | 197,536,000 | 181,439,000 | 169,254,000 | 166,716,000 | 155,288,000 | 145,598,000 | 136,684,000 | 134,310,000 | 120,695,000 | 116,908,000 | 109,858,000 | 110,726,000 | 105,999,000 | 3,518,000 | -9,396,000 | -10,553,000 | -4,094,000 | -2,352,000 | 2,334,000 | 3,039,000 | 2,149,000 | -8,965,000 | -8,884,000 | -9,314,000 | 66,557,000 | 60,353,000 | 58,356,000 | 47,219,000 | 46,818,000 | 48,036,000 | 46,308,000 | 42,953,000 | 38,399,000 | 36,274,000 | 34,623,000 | 5,056,000 | 36,794,000 | 38,373,000 | 38,960,000 | 37,752,000 | 35,756,000 | 33,607,000 | 29,699,000 | 26,715,000 | 24,493,000 | 23,496,000 | 22,888,456 | ||||
prepaid expenses and other current assets | 31,369,000 | 30,162,000 | 25,007,000 | 28,544,000 | 27,105,000 | 26,179,000 | 24,437,000 | 24,286,000 | 27,954,000 | 24,971,000 | 19,961,000 | 22,324,000 | 27,388,000 | 23,050,000 | 19,809,000 | 16,149,000 | 18,778,000 | 16,541,000 | 13,617,000 | 13,120,000 | 15,579,000 | 13,860,000 | 16,284,000 | 12,497,000 | 17,610,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid income taxes | 3,651,000 | 3,543,000 | 3,417,000 | 3,286,000 | 4,216,000 | 4,123,000 | 4,088,000 | 4,016,000 | 3,936,000 | 3,920,000 | 3,920,000 | 3,913,000 | 3,515,000 | 3,532,000 | 3,547,000 | 3,550,000 | 3,679,000 | 3,683,000 | 3,680,000 | 3,688,000 | 3,545,000 | 3,493,000 | 3,486,000 | 3,491,000 | 3,611,000 | 3,625,000 | 3,620,000 | 3,627,000 | 3,307,000 | 3,292,000 | 3,323,000 | 3,225,000 | 2,792,000 | 2,656,000 | 2,604,000 | 2,525,000 | 3,059,000 | 3,044,000 | 3,049,000 | 2,955,000 | 52,000 | -41,000 | 33,000 | 3,000 | 18,000 | 8,000 | 17,000 | -367,000 | 2,000 | -431,000 | ||||||||||||||||||||||||||||
income tax refund receivables | 2,152,000 | 5,785,000 | 80,000 | 2,335,000 | 8,185,000 | 4,335,000 | 453,000 | 859,000 | 9,432,000 | 4,365,000 | 1,069,000 | 779,000 | 4,164,000 | 464,000 | 1,803,000 | 2,777,000 | 2,561,000 | 3,543,000 | 3,331,000 | 3,549,000 | 11,812,000 | 10,467,000 | 5,586,000 | 3,151,000 | 9,566,000 | 4,876,000 | 1,317,000 | 933,000 | 1,043,000 | 2,331,000 | 1,327,000 | 1,211,000 | 91,000 | 43,000 | 680,000 | 423,000 | 373,000 | 43,000 | 504,000 | 905,000 | -539,000 | 11,000 | 10,000 | 24,000 | 192,000 | 1,267,000 | 2,000 | |||||||||||||||||||||||||||||||
total current assets | 985,533,000 | 923,072,000 | 958,635,000 | 923,774,000 | 1,078,317,000 | 1,162,546,000 | 1,105,275,000 | 1,108,470,000 | 585,318,000 | 594,907,000 | 557,217,000 | 529,084,000 | 499,863,000 | 492,631,000 | 478,092,000 | 482,212,000 | 463,442,000 | 449,782,000 | 438,488,000 | 429,707,000 | 434,626,000 | 445,945,000 | 462,508,000 | 454,538,000 | 441,302,000 | 426,946,000 | 421,783,000 | 429,834,000 | 387,649,000 | 370,964,000 | 343,770,000 | 316,121,000 | 299,865,000 | 295,560,000 | 272,151,000 | 243,423,000 | 234,294,000 | 219,977,000 | 210,009,000 | 204,003,000 | 123,956,000 | 115,388,000 | 112,451,000 | 95,588,000 | 94,145,000 | 91,529,000 | 87,625,000 | 94,592,000 | 102,201,000 | 93,264,000 | 88,438,000 | 76,409,000 | 75,443,000 | 76,716,000 | 70,146,000 | 69,032,000 | 66,793,000 | 65,112,000 | 68,400,000 | 74,636,000 | 76,375,000 | 80,798,942 | ||||||||||||||||
property and equipment: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
land and land improvements | 30,457,000 | 30,467,000 | 27,058,000 | 25,846,000 | 26,108,000 | 25,952,000 | 25,982,000 | 26,017,000 | 26,017,000 | 26,017,000 | 26,017,000 | 25,940,000 | 25,699,000 | 25,163,000 | 25,380,000 | 25,287,000 | 25,394,000 | 28,180,000 | 28,087,000 | 28,400,000 | 28,090,000 | 27,815,000 | 27,695,000 | 27,554,000 | 27,412,000 | 27,651,000 | 26,764,000 | 26,801,000 | 26,926,000 | 26,940,000 | 27,285,000 | 19,877,000 | 19,804,000 | 19,680,000 | 19,454,000 | 19,379,000 | 19,539,000 | 19,400,000 | 19,464,000 | 19,307,000 | 15,752,000 | 12,579,000 | 10,931,000 | 10,932,000 | 10,316,000 | 9,776,000 | 7,992,000 | 7,992,000 | 7,977,000 | 7,977,000 | 7,977,000 | 8,107,000 | 8,026,000 | 7,958,000 | 7,877,000 | 7,885,000 | 6,235,000 | 6,166,000 | 5,669,000 | 5,667,000 | ||||||||||||||||||
buildings | 198,563,000 | 198,505,000 | 193,561,000 | 192,296,000 | 192,323,000 | 191,030,000 | 191,218,000 | 191,491,000 | 190,825,000 | 189,900,000 | 189,947,000 | 189,148,000 | 186,976,000 | 188,550,000 | 189,773,000 | 190,044,000 | 190,335,000 | 188,089,000 | 187,774,000 | 188,878,000 | 182,914,000 | 181,749,000 | 153,896,000 | 153,863,000 | 152,782,000 | 153,502,000 | 152,974,000 | 151,251,000 | 150,880,000 | 150,726,000 | 148,278,000 | 147,356,000 | 144,084,000 | 143,059,000 | 141,065,000 | 139,119,000 | 139,559,000 | 139,140,000 | 137,890,000 | 136,595,000 | ||||||||||||||||||||||||||||||||||||||
manufacturing equipment | 357,135,000 | 353,119,000 | 345,272,000 | 340,864,000 | 334,787,000 | 330,290,000 | 327,628,000 | 316,930,000 | 313,600,000 | 306,925,000 | 303,547,000 | 299,089,000 | 290,306,000 | 286,257,000 | 283,802,000 | 277,976,000 | 275,155,000 | 272,084,000 | 270,754,000 | 268,894,000 | 266,755,000 | 257,493,000 | 247,878,000 | 244,368,000 | 234,121,000 | 230,315,000 | 225,402,000 | 221,029,000 | 211,215,000 | 205,911,000 | 204,053,000 | 197,651,000 | 193,061,000 | 188,329,000 | 186,323,000 | 178,110,000 | 171,308,000 | 166,034,000 | 161,503,000 | 158,775,000 | 101,660,000 | 94,176,000 | 85,572,000 | 83,997,000 | 78,965,000 | 75,019,000 | 73,640,000 | 70,482,000 | 66,797,000 | 65,708,000 | 64,487,000 | 61,531,000 | 55,656,000 | 55,008,000 | 53,266,000 | 50,218,000 | 48,164,000 | 42,409,000 | 34,243,000 | 33,253,000 | 31,155,000 | 30,646,287 | ||||||||||||||||
furniture and fixtures | 64,115,000 | 64,102,000 | 62,673,000 | 61,321,000 | 66,593,000 | 64,755,000 | 63,790,000 | 63,044,000 | 66,451,000 | 66,046,000 | 64,762,000 | 61,128,000 | 63,380,000 | 62,620,000 | 61,877,000 | 61,446,000 | 62,445,000 | 62,142,000 | 61,422,000 | 61,586,000 | 61,830,000 | 60,358,000 | 58,955,000 | 57,623,000 | 59,487,000 | 57,565,000 | 55,378,000 | 54,765,000 | 53,869,000 | 52,649,000 | 50,840,000 | 49,528,000 | 49,035,000 | 46,795,000 | 45,302,000 | 43,433,000 | 43,425,000 | 42,478,000 | 40,904,000 | 39,301,000 | 21,302,000 | 19,091,000 | 17,979,000 | 17,215,000 | 16,390,000 | 15,550,000 | 15,113,000 | 14,336,000 | 18,196,000 | 17,811,000 | 17,322,000 | 17,456,000 | 17,007,000 | 16,585,000 | 17,164,000 | 16,941,000 | 16,367,000 | 15,262,000 | 13,776,000 | 13,190,000 | 12,620,000 | 12,430,876 | ||||||||||||||||
leasehold improvements | 62,067,000 | 60,649,000 | 59,447,000 | 58,770,000 | 59,005,000 | 58,595,000 | 53,772,000 | 53,638,000 | 53,208,000 | 52,604,000 | 50,826,000 | 49,673,000 | 49,962,000 | 48,813,000 | 48,060,000 | 46,341,000 | 45,750,000 | 47,217,000 | 48,319,000 | 48,800,000 | 48,549,000 | 44,952,000 | 43,950,000 | 43,311,000 | 36,992,000 | 34,518,000 | 34,221,000 | 33,678,000 | 33,365,000 | 33,029,000 | 32,109,000 | 31,161,000 | 31,345,000 | 30,778,000 | 30,633,000 | 30,413,000 | 29,519,000 | 29,267,000 | 28,350,000 | 27,561,000 | 12,632,000 | 12,360,000 | 12,034,000 | 11,870,000 | 10,487,000 | 10,122,000 | 9,906,000 | 9,881,000 | 9,926,000 | 9,941,000 | 9,902,000 | 10,039,000 | 7,739,000 | 7,726,000 | 7,654,000 | 6,630,000 | 6,694,000 | 4,117,000 | 4,115,000 | 4,107,000 | 4,098,000 | 4,715,444 | ||||||||||||||||
construction-in-progress | 83,417,000 | 74,850,000 | 63,722,000 | 58,673,000 | 66,699,000 | 61,060,000 | 58,296,000 | 61,439,000 | 60,492,000 | 62,374,000 | 63,786,000 | 61,269,000 | 59,783,000 | 54,409,000 | 50,870,000 | 51,182,000 | 51,756,000 | 48,608,000 | 47,735,000 | 46,889,000 | 50,251,000 | 59,523,000 | 91,802,000 | 83,685,000 | 85,703,000 | 69,370,000 | 61,304,000 | 53,491,000 | 48,166,000 | 40,454,000 | 32,986,000 | 32,896,000 | 34,625,000 | 31,975,000 | 29,259,000 | 28,180,000 | 33,073,000 | 31,795,000 | 30,837,000 | 26,292,000 | 41,517,000 | 21,903,000 | 15,964,000 | 11,609,000 | 14,371,000 | 11,476,000 | 9,219,000 | 9,103,000 | 7,932,000 | 6,692,000 | 10,619,000 | 8,565,000 | 14,315,000 | 11,148,000 | 7,874,000 | 8,431,000 | 8,270,000 | 13,454,000 | 29,464,000 | 21,600,000 | 20,859,000 | 12,620,085 | ||||||||||||||||
total property and equipment | 795,754,000 | 781,692,000 | 751,733,000 | 737,770,000 | 745,515,000 | 731,682,000 | 720,686,000 | 712,559,000 | 710,593,000 | 703,866,000 | 698,885,000 | 686,247,000 | 676,106,000 | 665,812,000 | 659,762,000 | 652,276,000 | 650,835,000 | 646,320,000 | 644,091,000 | 643,447,000 | 638,389,000 | 631,890,000 | 624,176,000 | 610,404,000 | 596,497,000 | 572,921,000 | 556,043,000 | 541,015,000 | 524,421,000 | 509,709,000 | 495,551,000 | 478,469,000 | 471,954,000 | 460,616,000 | 452,036,000 | 438,634,000 | 436,423,000 | 428,114,000 | 418,948,000 | 407,831,000 | ||||||||||||||||||||||||||||||||||||||
less accumulated depreciation | -377,750,000 | -371,707,000 | -361,409,000 | -351,605,000 | -355,862,000 | -345,743,000 | -337,025,000 | -329,036,000 | -327,267,000 | -319,504,000 | -311,435,000 | -303,271,000 | -299,950,000 | -294,361,000 | -287,853,000 | -280,618,000 | -277,379,000 | -272,519,000 | -265,914,000 | -260,719,000 | -254,585,000 | -248,261,000 | -239,316,000 | -231,619,000 | -229,596,000 | -222,402,000 | -215,279,000 | -209,563,000 | -204,496,000 | -197,941,000 | -191,826,000 | -185,649,000 | -181,672,000 | -175,413,000 | -168,652,000 | -162,061,000 | -157,797,000 | -151,628,000 | -146,057,000 | -140,053,000 | -81,412,000 | |||||||||||||||||||||||||||||||||||||
property and equipment — net | 418,004,000 | 409,985,000 | 390,324,000 | 386,165,000 | 389,653,000 | 385,939,000 | 383,661,000 | 383,523,000 | 383,326,000 | 384,362,000 | 387,450,000 | 382,976,000 | 376,156,000 | 371,451,000 | 371,909,000 | 371,658,000 | 373,456,000 | 373,801,000 | 378,177,000 | 382,728,000 | 383,804,000 | 383,629,000 | 384,860,000 | 378,785,000 | 366,901,000 | 350,519,000 | 340,764,000 | 331,452,000 | 319,925,000 | 311,768,000 | 303,725,000 | 292,820,000 | 290,282,000 | 285,203,000 | 283,384,000 | 276,573,000 | 278,626,000 | 276,486,000 | 272,891,000 | 267,778,000 | ||||||||||||||||||||||||||||||||||||||
other assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2025 — 433,630 and 2024 — 377,993 | 468,819,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2025 — 93,600 and 2024 — 85,343 | 69,581,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill | 507,427,000 | 504,555,000 | 464,360,000 | 463,511,000 | 399,448,000 | 381,433,000 | 381,539,000 | 382,240,000 | 381,052,000 | 381,767,000 | 360,291,000 | 359,821,000 | 358,056,000 | 359,692,000 | 361,456,000 | 361,741,000 | 362,000,000 | 362,810,000 | 362,500,000 | 363,533,000 | 353,622,000 | 353,093,000 | 352,242,000 | 353,193,000 | 352,158,000 | 352,133,000 | 334,951,000 | 335,433,000 | 249,023,000 | 248,998,000 | 244,125,000 | 238,147,000 | 234,043,000 | 226,829,000 | 219,911,000 | 211,927,000 | 213,069,000 | 187,034,000 | 187,047,000 | 184,472,000 | 61,144,000 | 58,659,000 | 54,738,000 | 33,002,000 | 33,002,000 | 32,849,000 | 32,567,000 | 21,124,000 | 11,680,000 | 11,680,000 | 11,651,000 | 9,099,000 | 9,068,000 | 9,684,000 | 8,090,000 | 7,579,000 | 6,470,000 | 5,750,000 | 5,738,000 | 5,717,000 | 4,765,000 | 4,764,596 | ||||||||||||||||
deferred income tax assets | 16,284,000 | 16,243,000 | 16,100,000 | 16,044,000 | 7,253,000 | 7,013,000 | 7,072,000 | 7,288,000 | 6,438,000 | 6,492,000 | 6,665,000 | 6,599,000 | 5,467,000 | 5,861,000 | 6,179,000 | 6,080,000 | 4,581,000 | 4,614,000 | 4,529,000 | 4,597,000 | 3,857,000 | 3,748,000 | 3,716,000 | 3,788,000 | 2,944,000 | 3,038,000 | 3,083,000 | 3,001,000 | 2,254,000 | 2,318,000 | 2,441,000 | 8,219,000 | 6,408,000 | 7,017,000 | 7,049,000 | 7,025,000 | 4,591,000 | 4,651,000 | 5,005,000 | 3,289,000 | 3,287,000 | 2,783,000 | 2,781,000 | 2,779,000 | 2,083,000 | 2,087,000 | 2,087,000 | 3,000 | 3,000 | 163,000 | 28,000 | 28,000 | 24,000 | 41,000 | 41,000 | 38,000 | 677,212 | |||||||||||||||||||||
right-of-use operating lease assets | 88,496,000 | 89,279,000 | 87,722,000 | 65,508,000 | 68,867,000 | 69,903,000 | 72,639,000 | 63,047,000 | 63,633,000 | 62,436,000 | 62,881,000 | 65,262,000 | 64,700,000 | 64,353,000 | 64,659,000 | 65,913,000 | 68,078,000 | 70,767,000 | 74,714,000 | 78,240,000 | 76,775,000 | 79,051,000 | 79,133,000 | 80,244,000 | 79,757,000 | 79,309,000 | 80,453,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
other assets | 76,854,000 | 80,753,000 | 71,856,000 | 65,336,000 | 62,382,000 | 61,583,000 | 58,682,000 | 54,793,000 | 48,545,000 | 52,492,000 | 45,721,000 | 44,352,000 | 44,388,000 | 43,303,000 | 41,707,000 | 41,421,000 | 40,672,000 | 37,827,000 | 37,286,000 | 37,676,000 | 35,011,000 | 36,413,000 | 36,569,000 | 41,461,000 | 59,735,000 | 58,255,000 | 60,052,000 | 57,579,000 | 61,927,000 | 58,075,000 | 37,271,000 | 35,040,000 | 32,412,000 | 31,056,000 | 29,098,000 | 28,012,000 | 16,296,000 | 14,770,000 | 13,664,000 | 13,121,000 | -602,000 | -1,388,000 | -1,128,000 | -641,000 | -847,000 | -1,806,000 | -813,000 | -377,000 | -1,178,000 | -869,000 | -283,000 | 8,053,000 | 9,664,000 | 7,265,000 | 6,592,000 | 6,483,000 | 3,030,000 | 2,730,000 | 2,181,000 | 2,911,000 | 2,844,000 | 2,921,000 | 2,830,000 | 102,000 | 2,659,000 | 2,424,000 | 2,552,000 | 2,254,000 | 1,980,000 | 1,856,000 | 1,441,000 | 1,268,768 | ||||||
total other assets | 1,227,461,000 | 1,252,988,000 | 1,119,014,000 | 1,108,664,000 | 910,114,000 | 823,354,000 | 837,416,000 | 833,251,000 | 839,861,000 | 858,299,000 | 739,442,000 | 751,906,000 | 756,718,000 | 767,437,000 | 779,739,000 | 794,424,000 | 806,268,000 | 818,810,000 | 835,054,000 | 851,961,000 | 852,080,000 | 886,295,000 | 901,904,000 | 923,998,000 | 953,501,000 | 958,805,000 | 927,246,000 | 858,726,000 | 602,309,000 | 608,459,000 | 591,714,000 | 502,870,000 | 497,004,000 | 471,088,000 | 459,646,000 | 422,807,000 | 415,679,000 | 318,502,000 | 320,520,000 | 306,947,000 | 132,354,000 | 129,447,000 | 129,117,000 | 66,552,000 | 66,779,000 | 61,908,000 | 61,927,000 | 40,810,000 | 21,997,000 | 21,576,000 | 21,586,000 | 18,468,000 | 17,456,000 | 17,306,000 | 15,150,000 | 13,701,000 | 12,447,000 | 10,879,000 | 10,632,000 | 10,477,000 | 8,275,000 | 8,266,689 | ||||||||||||||||
total assets | 2,630,998,000 | 2,586,045,000 | 2,467,973,000 | 2,418,603,000 | 2,378,084,000 | 2,371,839,000 | 2,326,352,000 | 2,325,244,000 | 1,808,505,000 | 1,837,568,000 | 1,684,109,000 | 1,663,966,000 | 1,632,737,000 | 1,631,519,000 | 1,629,740,000 | 1,648,294,000 | 1,643,166,000 | 1,642,393,000 | 1,651,719,000 | 1,664,396,000 | 1,670,510,000 | 1,715,869,000 | 1,749,272,000 | 1,757,321,000 | 418,833,000 | 380,417,000 | 364,042,000 | 280,212,000 | 277,136,000 | 264,631,000 | 257,065,000 | 241,150,000 | 227,922,000 | 217,435,000 | 210,759,000 | 193,165,000 | 190,596,000 | 189,443,000 | 177,107,000 | 172,720,000 | 166,074,000 | 158,981,000 | 153,417,000 | 146,340,000 | 128,994,000 | 125,498,399 | ||||||||||||||||||||||||||||||||
liabilities and stockholders’ equity | 2,025,000 | 2,025,000 | 2,024,000 | 2,024,000 | 2,024,000 | 2,024,000 | 2,023,000 | 2,023,000 | 2,023,000 | 2,023,000 | 2,022,000 | 2,022,000 | 2,022,000 | 2,022,000 | 2,021,000 | 2,021,000 | 2,021,000 | 2,021,000 | 2,020,000 | 2,006,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade payables | 64,746,000 | 63,759,000 | 68,502,000 | 60,808,000 | 55,573,000 | 48,377,000 | 65,944,000 | 48,862,000 | 61,761,000 | 65,588,000 | 68,504,000 | 63,206,000 | 59,441,000 | 58,099,000 | 55,624,000 | 51,077,000 | 53,809,000 | 52,986,000 | 49,837,000 | 46,634,000 | 44,444,000 | 56,012,000 | 54,623,000 | 52,387,000 | 52,601,000 | 51,680,000 | 54,024,000 | 50,697,000 | 50,823,000 | 43,739,000 | 34,931,000 | 32,291,000 | 36,671,000 | 32,625,000 | 30,619,000 | 30,192,000 | 31,286,000 | 39,104,000 | 37,977,000 | 84,000 | 5,326,000 | 655,000 | 2,299,000 | -485,000 | -5,000 | 586,000 | -2,084,000 | 7,721,000 | 5,805,000 | -2,129,000 | 13,456,000 | 296,000 | 13,570,000 | 14,304,000 | 13,191,000 | 11,709,000 | 11,246,000 | 10,158,000 | 11,140,000 | 11,818,000 | 305,000 | 11,270,000 | 10,758,000 | 10,427,000 | 12,506,000 | 13,054,000 | 12,359,000 | 8,727,000 | 8,600,311 | |||||||||
accrued expenses | 147,377,000 | 118,679,000 | 134,077,000 | 127,255,000 | 117,574,000 | 113,220,000 | 120,447,000 | 119,291,000 | 110,662,000 | 119,197,000 | 123,189,000 | 124,504,000 | 111,955,000 | 122,394,000 | 159,014,000 | 141,929,000 | 135,013,000 | 132,173,000 | 111,944,000 | 116,927,000 | 106,934,000 | 87,095,000 | 105,184,000 | 80,486,000 | 97,176,000 | 91,310,000 | 96,173,000 | 65,530,000 | 65,838,000 | 57,531,000 | 58,932,000 | 56,508,000 | 59,185,000 | 52,875,000 | 44,947,000 | 44,927,000 | 40,196,000 | 33,866,000 | 37,846,000 | 2,653,000 | 6,137,000 | 4,686,000 | 3,539,000 | 2,868,000 | -276,000 | -3,705,000 | -2,280,000 | 4,448,000 | 2,793,000 | 1,334,000 | 14,309,000 | 1,628,000 | 13,213,000 | 12,182,000 | 11,553,000 | 10,856,000 | 9,821,000 | 872,000 | 9,880,000 | 9,794,000 | 8,684,000 | 8,827,000 | 9,853,000 | 8,549,000 | 9,121,000 | 8,651,000 | 7,667,000 | 7,385,000 | 7,884,561 | |||||||||
short-term operating lease liabilities | 10,612,000 | 9,435,000 | 10,331,000 | 11,469,000 | 11,743,000 | 12,472,000 | 12,087,000 | 11,688,000 | 11,531,000 | 10,898,000 | 11,005,000 | 10,310,000 | 10,444,000 | 10,304,000 | 10,668,000 | 11,119,000 | 11,721,000 | 12,246,000 | 12,903,000 | 12,981,000 | 12,886,000 | 11,670,000 | 11,550,000 | 11,652,000 | 11,732,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes payable | 7,740,000 | 4,950,000 | 3,492,000 | 1,547,000 | 1,325,000 | 9,275,000 | 5,086,000 | 3,542,000 | 2,299,000 | 9,019,000 | 6,697,000 | 3,765,000 | 3,437,000 | 3,659,000 | 2,536,000 | 1,850,000 | 2,561,000 | 2,773,000 | 2,820,000 | 2,005,000 | 2,460,000 | 3,014,000 | 2,799,000 | 1,188,000 | 42,000 | 1,644,000 | 3,146,000 | 1,598,000 | 948,000 | 2,397,000 | 2,298,000 | 1,435,000 | 1,910,000 | 2,120,000 | 2,193,000 | 809,000 | 3,138,000 | 2,145,000 | 1,498,000 | 1,377,000 | 1,083,000 | 3,248,000 | 759,000 | 91,000 | 255,000 | -1,319,000 | -34,000 | 2,057,000 | 2,670,000 | 2,658,000 | 2,246,000 | 825,000 | 1,472,000 | 2,161,000 | 2,109,000 | 846,000 | 2,334,000 | 1,595,000 | 138,000 | 401,000 | 819,000 | 2,724,000 | 1,541,000 | 1,448,000 | 1,223,000 | 1,016,000 | 1,578,000 | 3,237,000 | 1,076,000 | 2,239,977 | ||||||||
total current liabilities | 230,475,000 | 196,823,000 | 216,402,000 | 201,079,000 | 186,215,000 | 183,344,000 | 203,564,000 | 187,133,000 | 190,003,000 | 215,952,000 | 220,645,000 | 213,035,000 | 195,590,000 | 203,831,000 | 236,280,000 | 213,475,000 | 210,604,000 | 207,678,000 | 185,004,000 | 186,047,000 | 174,224,000 | 165,291,000 | 181,656,000 | 153,213,000 | 176,551,000 | 178,459,000 | 175,343,000 | 139,825,000 | 139,594,000 | 124,400,000 | 115,620,000 | 107,738,000 | 114,927,000 | 105,097,000 | 88,331,000 | 86,472,000 | 85,093,000 | 85,322,000 | 87,910,000 | 30,656,000 | 35,660,000 | 36,075,000 | 27,167,000 | 25,252,000 | 25,162,000 | 20,487,000 | 21,647,000 | 21,553,000 | 22,662,000 | 23,053,000 | 20,995,000 | 23,645,000 | 24,064,000 | 23,863,000 | 17,335,000 | 18,932,946 | ||||||||||||||||||||||
long-term debt | 732,916,000 | 730,673,000 | 729,551,000 | 750,505,000 | 801,321,000 | 800,136,000 | 823,013,000 | 282,370,000 | 335,232,000 | 186,423,000 | 186,759,000 | 205,412,000 | 235,703,000 | 243,112,000 | 234,397,000 | 271,181,000 | 284,900,000 | 312,875,000 | 343,722,000 | 349,813,000 | 402,915,000 | 438,137,000 | 431,984,000 | 432,456,000 | 385,221,000 | 362,187,000 | 373,152,000 | 186,867,000 | 391,582,000 | 365,797,000 | 259,013,000 | 260,978,000 | 224,943,000 | 220,408,000 | 314,373,000 | 317,760,000 | 221,719,000 | 218,402,000 | 197,593,000 | 3,000 | 3,000 | 4,000 | 3,000 | 5,000 | 5,000 | |||||||||||||||||||||||||||||||||
deferred income tax liabilities | 26,707,000 | 247,000 | 240,000 | 5,571,000 | 5,510,000 | 5,519,000 | 5,547,000 | 18,458,000 | 18,477,000 | 18,478,000 | 18,462,000 | 31,168,000 | 31,195,000 | 31,491,000 | 31,503,000 | 33,238,000 | 33,271,000 | 33,252,000 | 33,312,000 | 45,439,000 | 45,236,000 | 45,027,000 | 45,236,000 | 58,290,000 | 60,932,000 | 56,324,000 | 56,363,000 | 23,102,000 | 23,148,000 | 23,330,000 | 23,289,000 | 23,764,000 | 23,354,000 | 20,482,000 | 25,981,000 | 21,886,000 | 11,024,000 | 11,099,000 | 10,985,000 | 11,068,000 | 8,788,000 | 8,789,000 | 8,782,000 | 6,511,000 | 6,533,000 | 97,000 | 4,812,000 | 4,344,000 | 812,000 | 720,000 | 568,000 | 768,000 | 503,000 | 449,000 | 2,991,000 | 3,218,893 | ||||||||||||||||||||||
liabilities related to unrecognized tax benefits | 2,169,000 | 2,118,000 | 2,118,000 | 1,912,000 | 1,912,000 | 1,912,000 | 1,912,000 | 1,912,000 | 1,912,000 | 1,912,000 | 1,912,000 | 932,000 | 932,000 | 932,000 | 932,000 | 1,016,000 | 1,016,000 | 1,016,000 | 1,016,000 | 1,990,000 | 1,990,000 | 1,990,000 | 1,990,000 | 3,013,000 | 3,013,000 | 3,013,000 | 3,013,000 | 2,746,000 | 2,746,000 | 2,746,000 | 2,746,000 | 438,000 | 438,000 | 438,000 | 438,000 | 402,000 | 768,000 | 768,000 | 768,000 | -76,000 | -844,000 | -264,000 | -520,000 | -209,000 | -993,000 | -226,000 | 2,945,000 | |||||||||||||||||||||||||||||||
deferred compensation payable | 17,083,000 | 18,617,000 | 19,197,000 | 19,218,000 | 18,588,000 | 18,228,000 | 17,167,000 | 15,508,000 | 16,418,000 | 15,868,000 | 15,264,000 | 14,786,000 | 15,562,000 | 16,804,000 | 18,111,000 | 17,414,000 | 17,055,000 | 16,227,000 | 16,808,000 | 15,396,000 | 14,194,000 | 14,066,000 | 14,855,000 | 13,497,000 | 12,739,000 | 12,480,000 | 11,219,000 | 12,176,000 | 11,620,000 | 11,185,000 | 11,181,000 | 10,319,000 | 9,725,000 | 9,399,000 | 9,211,000 | 9,000,000 | 9,103,000 | 8,195,000 | 8,500,000 | 473,000 | 802,000 | 644,000 | 532,000 | 282,000 | 1,877,000 | 647,000 | 281,000 | 1,371,000 | 838,000 | 327,000 | 3,417,000 | 1,034,000 | 3,048,000 | 2,736,000 | 2,205,000 | 3,207,000 | 3,048,000 | 2,893,000 | 3,022,000 | 2,950,000 | 2,594,000 | 2,586,000 | 2,588,000 | 2,211,000 | 2,064,000 | 1,918,000 | 1,470,000 | 1,281,982 | ||||||||||
deferred credits | 1,424,000 | 1,476,000 | 1,502,000 | 1,527,000 | 1,553,000 | 1,579,000 | 1,605,000 | 1,631,000 | 1,657,000 | 1,682,000 | 1,708,000 | 1,735,000 | 1,762,000 | 1,788,000 | 1,815,000 | 1,842,000 | 1,869,000 | 1,896,000 | 1,923,000 | 1,948,000 | 2,053,000 | 2,088,000 | 2,122,000 | 2,157,000 | 2,192,000 | 2,227,000 | 2,261,000 | 2,296,000 | 2,332,000 | 2,367,000 | 2,403,000 | 2,439,000 | 2,474,000 | 2,510,000 | 2,550,000 | 2,593,000 | 2,635,000 | 2,678,000 | 2,721,000 | 1,817,000 | 1,903,000 | 1,931,000 | 1,967,000 | 2,052,000 | 2,078,000 | 2,134,000 | 2,167,000 | 2,200,000 | 2,280,000 | 2,325,000 | 2,370,000 | 2,462,000 | 2,510,000 | 2,561,000 | 1,352,000 | 1,404,884 | ||||||||||||||||||||||
long-term operating lease liabilities | 77,624,000 | 77,549,000 | 54,783,000 | 57,178,000 | 58,036,000 | 60,141,000 | 56,259,000 | 57,455,000 | 56,599,000 | 57,893,000 | 59,736,000 | 59,989,000 | 59,646,000 | 60,366,000 | 61,526,000 | 63,505,000 | 65,841,000 | 67,980,000 | 70,941,000 | 69,407,000 | 71,785,000 | 71,642,000 | 72,714,000 | 72,056,000 | 71,272,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term obligations | 13,192,000 | 12,047,000 | 15,451,000 | 17,341,000 | 15,912,000 | 14,956,000 | 13,830,000 | 13,806,000 | 13,223,000 | 13,899,000 | 14,736,000 | 16,492,000 | 17,475,000 | 14,550,000 | 23,584,000 | 27,772,000 | 35,056,000 | 33,756,000 | 52,748,000 | 66,286,000 | 74,278,000 | 70,886,000 | 56,473,000 | 77,389,000 | 73,283,000 | 62,357,000 | 65,494,000 | 14,814,000 | 16,069,000 | 16,027,000 | 16,379,000 | 14,659,000 | 9,508,000 | 4,505,000 | 3,730,000 | 4,546,000 | 4,633,000 | 4,632,000 | 4,148,000 | 433,000 | 566,000 | 764,000 | 446,000 | -50,000 | -4,399,000 | -127,000 | 294,000 | -89,000 | 314,000 | -70,000 | 263,000 | 461,000 | 386,000 | 395,000 | 371,000 | 435,000 | 528,000 | |||||||||||||||||||||
total liabilities | 1,101,590,000 | 1,039,550,000 | 1,039,244,000 | 1,054,678,000 | 1,089,394,000 | 1,086,162,000 | 1,123,244,000 | 578,620,000 | 633,868,000 | 512,454,000 | 519,569,000 | 543,896,000 | 558,212,000 | 573,221,000 | 608,495,000 | 629,790,000 | 649,959,000 | 675,027,000 | 705,821,000 | 736,673,000 | 787,022,000 | 809,474,000 | 807,377,000 | 812,463,000 | 785,595,000 | 749,682,000 | 687,237,000 | 386,672,000 | 591,937,000 | 550,698,000 | 435,477,000 | 420,335,000 | 385,369,000 | 362,839,000 | 444,614,000 | 442,659,000 | 334,975,000 | 331,096,000 | 312,625,000 | 50,166,000 | 52,541,000 | 52,735,000 | 43,334,000 | 39,981,000 | 39,798,000 | 34,878,000 | 36,033,000 | 34,917,000 | 31,735,000 | 32,186,000 | 30,188,000 | 30,927,000 | 31,133,000 | 30,897,000 | 23,148,000 | 24,838,705 | ||||||||||||||||||||||
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stockholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized; no shares issued as of september 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock | 747,103,000 | 718,111,000 | 703,219,000 | 669,207,000 | 658,724,000 | 649,222,000 | 638,150,000 | 695,181,000 | 691,523,000 | 681,108,000 | 675,174,000 | 658,198,000 | 651,926,000 | 646,370,000 | 641,533,000 | 633,948,000 | 623,591,000 | 615,113,000 | 606,224,000 | 600,737,000 | 595,726,000 | 590,065,000 | 587,017,000 | 584,161,000 | 579,250,000 | 574,946,000 | 571,383,000 | 568,051,000 | 359,570,000 | 356,228,000 | 353,392,000 | 351,321,000 | 348,051,000 | 344,497,000 | 206,186,000 | 204,601,000 | 200,015,000 | 199,003,000 | 197,826,000 | |||||||||||||||||||||||||||||||||||||||
retained earnings | 786,024,000 | 725,688,000 | 695,541,000 | 667,594,000 | 639,150,000 | 603,424,000 | 575,184,000 | 547,555,000 | 521,721,000 | 501,476,000 | 480,773,000 | 447,372,000 | 432,100,000 | 416,802,000 | 406,257,000 | 385,644,000 | 373,677,000 | 368,761,000 | 357,803,000 | 342,425,000 | 345,434,000 | 364,492,000 | 368,221,000 | 373,174,000 | 376,572,000 | 369,713,000 | 363,425,000 | 354,236,000 | 337,618,000 | 326,677,000 | 321,408,000 | 314,602,000 | 318,171,000 | 308,688,000 | 293,885,000 | 286,378,000 | 285,405,000 | 278,115,000 | 273,764,000 | 165,427,000 | 150,137,000 | 144,052,000 | 138,211,000 | 122,082,000 | 116,264,000 | 107,220,000 | 102,925,000 | 99,329,000 | 93,916,000 | 90,591,000 | 87,069,000 | 80,974,000 | 77,647,000 | 72,965,000 | 64,594,000 | 60,405,915 | ||||||||||||||||||||||
accumulated other comprehensive loss | -3,719,000 | -15,376,000 | -19,401,000 | -13,395,000 | -15,429,000 | -12,456,000 | -11,334,000 | -12,851,000 | -9,544,000 | -10,929,000 | -11,550,000 | -16,729,000 | -10,719,000 | -6,653,000 | -7,991,000 | -6,216,000 | -4,834,000 | -7,182,000 | -5,452,000 | -9,325,000 | -12,313,000 | -14,759,000 | -5,294,000 | -8,094,000 | -5,147,000 | -4,548,000 | -843,000 | -1,882,000 | -5,039,000 | -5,430,000 | -4,794,000 | -5,487,000 | ||||||||||||||||||||||||||||||||||||||||||||||
total stockholders’ equity | 1,529,408,000 | 1,428,423,000 | 1,379,359,000 | 1,323,406,000 | 1,282,445,000 | 1,240,190,000 | 1,202,000,000 | 1,229,885,000 | 1,203,700,000 | 1,171,655,000 | 1,144,397,000 | 1,088,841,000 | 1,073,307,000 | 1,056,519,000 | 1,039,799,000 | 1,013,376,000 | 992,434,000 | 976,692,000 | 958,575,000 | 933,837,000 | 928,847,000 | 939,798,000 | 949,944,000 | 949,241,000 | 950,675,000 | 940,111,000 | 932,775,000 | 923,211,000 | 699,254,000 | 688,511,000 | 676,334,000 | 666,816,000 | 666,482,000 | 652,342,000 | 498,189,000 | 485,940,000 | 479,990,000 | 472,324,000 | 466,103,000 | 230,046,000 | 212,090,000 | 204,330,000 | 197,816,000 | 177,454,000 | 170,961,000 | 158,287,000 | 154,563,000 | 154,526,000 | 145,372,000 | 140,534,000 | 135,886,000 | 128,054,000 | 122,284,000 | 115,443,000 | 105,846,000 | 100,659,694 | ||||||||||||||||||||||
total liabilities and stockholders’ equity | 2,630,998,000 | 2,467,973,000 | 2,418,603,000 | 2,378,084,000 | 2,371,839,000 | 2,326,352,000 | 2,325,244,000 | 1,808,505,000 | 1,837,568,000 | 1,684,109,000 | 1,663,966,000 | 1,632,737,000 | 1,631,519,000 | 1,629,740,000 | 1,648,294,000 | 1,643,166,000 | 1,642,393,000 | 280,212,000 | 264,631,000 | 257,065,000 | 241,150,000 | 217,435,000 | 210,759,000 | 193,165,000 | 190,596,000 | 189,443,000 | 177,107,000 | 172,720,000 | 166,074,000 | 158,981,000 | 153,417,000 | 146,340,000 | 128,994,000 | 125,498,399 | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2025 — 10,108 and 2024 — 9,729 | 204,162,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2025 — 414,713 and 2024 — 377,993 | 489,975,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2025 — 90,872 and 2024 — 85,343 | 72,183,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
see condensed notes to consolidated financial statements. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2025 — 10,708 and 2024 — 9,729 | 199,550,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2025 — 395,575 and 2024 — 377,993 | 414,348,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2025 — 87,986 and 2024 — 85,343 | 64,628,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized; no shares issued as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2024 — 9,729 and 2023 — 9,023 | 190,243,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2024 — 377,993 and 2023 — 321,488 | 431,766,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2024 — 85,343 and 2023 — 76,887 | 66,499,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term income taxes payable | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 347,000 | 392,000 | 392,000 | 392,000 | 392,000 | 4,846,000 | 4,846,000 | 4,846,000 | 4,846,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized; no shares issued as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2024 — 9,266 and 2023 — 9,023 | 189,831,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2024 — 361,725 and 2023 — 321,488 | 322,325,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2024 — 82,979 and 2023 — 76,887 | 49,839,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized; no shares issued as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2024 — 9,276 and 2023 — 9,023 | 182,415,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2024 — 346,763 and 2023 — 321,488 | 264,195,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2024 — 80,628 and 2023 — 76,887 | 39,227,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized; no shares issued as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2024 — 9,327 and 2023 — 9,023 | 180,663,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2024 — 333,920 and 2023 — 321,488 | 277,085,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2024 — 78,771 and 2023 — 76,887 | 40,399,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized; no shares issued as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2023 — 9,023 and 2022 — 8,423 | 177,885,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2023 — 321,488 and 2022 — 274,570 | 283,999,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2023 — 76,887 and 2022 — 69,780 | 41,884,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt | 3,750,000 | 3,750,000 | 11,250,000 | 11,250,000 | 11,250,000 | 10,313,000 | 9,375,000 | 8,438,000 | 7,500,000 | 7,500,000 | 7,500,000 | 7,500,000 | 7,500,000 | 7,500,000 | 7,500,000 | 7,500,000 | 7,500,000 | 15,000,000 | 22,000,000 | 22,000,000 | 22,000,000 | 21,985,000 | 20,733,000 | 19,459,000 | 16,962,000 | 16,969,000 | 16,998,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 1,000 | 1,000 | 1,000 | 2,000 | 4,000 | 5,000 | ||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2023 and december 31, 2022; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2023 — 8,721 and 2022 — 8,423 | 167,824,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2023 — 308,889 and 2022 — 274,570 | 296,349,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2023 — 76,909 and 2022 — 69,780 | 43,844,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2023 and december 31, 2022; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2023 — 8,652 and 2022 — 8,423 | 170,990,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2023 — 296,131 and 2022 — 274,570 | 309,228,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2023 — 74,418 and 2022 — 69,780 | 45,884,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2023 and december 31, 2022; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2023 — 8,248 and 2022 — 8,423 | 170,182,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2023 — 285,008 and 2022 — 274,570 | 227,203,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2023 — 71,742 and 2022 — 69,780 | 36,681,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2023 and december 31, 2022; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2022 — 8,423 and 2021 — 6,767 | 164,677,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2022 — 274,570 and 2021 — 234,016 | 237,522,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2022 — 69,780 and 2021 — 65,053 | 38,350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2022 and december 31, 2021; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2022 — 8,018 and 2021 — 6,767 | 155,828,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2022 — 263,990 and 2021 — 234,016 | 245,282,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2022 — 68,308 and 2021 — 65,053 | 38,825,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2022 and december 31, 2021; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2022 — 7,738 and 2021 — 6,767 | 158,801,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2022 — 254,031 and 2021 — 234,016 | 254,557,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2022 — 66,591 and 2021 — 65,053 | 39,671,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2022 — 7,568 and 2021 — 6,767 | 155,859,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2022 — 244,017 and 2021 — 234,016 | 264,839,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2022 — 66,924 and 2021 — 65,053 | 40,899,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2021 — 6,767 and 2020 — 5,313 | 152,301,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2021 — 234,016 and 2020 — 193,164 | 276,833,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2021 — 65,053 and 2020 — 56,943 | 42,436,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2021 and december 31, 2020; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2021 — 6,444 and 2020 — 5,313 | 150,780,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2021 — 223,814 and 2020 — 193,164 | 287,117,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2021 — 63,030 and 2020 — 56,943 | 43,820,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2021 and december 31, 2020; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2021 — 5,652 and 2020 — 5,313 | 153,443,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2021 — 213,621 and 2020 — 193,164 | 297,471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2021 — 60,993 and 2020 — 56,943 | 45,321,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2021 and december 31, 2020; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2021 — 5,953 and 2020 — 5,313 | 150,314,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2021 — 203,308 and 2020 — 193,164 | 307,713,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2021 — 59,025 and 2020 — 56,943 | 48,312,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2021 and december 31, 2020; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders' equity | 1,651,719,000 | 1,664,396,000 | 1,670,510,000 | 1,715,869,000 | 1,749,272,000 | 1,757,321,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for credit losses — 2020 — 5,313 and 2019 — 3,108 | 146,641,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2020 — 193,164 and 2019 — 149,947 | 318,059,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2020 — 56,943 and 2019 — 65,607 | 49,856,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2020 and december 31, 2019; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2020 — 4,687 and 2019 — 3,108 | 141,957,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2020 — 182,148 and 2019 — 149,947 | 331,851,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2020 — 56,913 and 2019 — 65,607 | 50,964,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2020 and december 31, 2019; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2020 — 3,866 and 2019 — 3,108 | 138,792,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2020 — 174,495 and 2019 — 149,947 | 354,273,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2020 — 59,926 and 2019 — 65,607 | 59,717,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2020 and december 31, 2019; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2020 — 4,124 and 2019 — 3,108 | 150,050,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2020 — 162,135 and 2019 — 149,947 | 366,551,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2020 — 59,934 and 2019 — 65,607 | 63,693,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2020 and december 31, 2019; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2019 — 3,108 and 2018 — 2,355 | 155,365,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2019 — 149,947 and 2018 — 102,357 | 379,529,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2019 — 65,607 and 2018 — 49,136 | 65,783,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2019 and december 31, 2018; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,848 and 2018 — 2,355 | 144,683,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization —2019 — 137,551 and 2018 — 102,357 | 390,796,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2019 — 62,378 and 2018 — 49,136 | 68,111,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total | 1,761,704,000 | 1,736,270,000 | 1,689,793,000 | 1,620,012,000 | 1,309,883,000 | 1,291,191,000 | 1,239,209,000 | 1,111,811,000 | 1,087,151,000 | 1,051,851,000 | 1,015,181,000 | 942,803,000 | 928,599,000 | 814,965,000 | 803,420,000 | 778,728,000 | 243,935,000 | 210,508,000 | 192,617,000 | 185,391,000 | 180,824,000 | 171,943,000 | 165,773,000 | 161,659,000 | 160,234,000 | 157,254,000 | 153,548,000 | 148,809,000 | 145,802,000 | 141,462,000 | 136,392,000 | 132,638,000 | 128,217,000 | 120,991,000 | 110,969,000 | 96,657,000 | 77,510,000 | 68,510,443 | ||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2019 and december 31, 2018; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,656 and 2018 — 2,355 | 156,444,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and current other assets | 12,305,000 | 11,220,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2019 — 125,447 and 2018 — 102,357 | 391,651,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2019 — 56,289 and 2018 — 49,136 | 74,419,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsjune 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2019 and december 31, 2018; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,406 and 2018 — 2,355 | 146,488,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2019 — 113,765 and 2018 — 102,357 | 371,603,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2019 — 52,469 and 2018 — 49,136 | 77,104,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term operating lease liability | 11,825,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term operating lease liability | 72,243,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2019 and december 31, 2018; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2018 — 2,355 and 2017 — 1,769 | 137,174,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | 11,326,000 | 11,720,000 | 12,142,000 | 10,360,000 | 9,096,000 | 20,581,000 | 9,105,000 | 7,778,000 | 6,226,000 | 4,302,000 | 3,988,000 | 2,946,000 | 3,047,000 | 2,238,000 | 1,832,000 | 1,959,000 | 1,184,000 | 1,482,000 | 1,655,000 | 1,072,000 | 1,463,000 | 1,702,000 | 1,241,000 | 6,000 | 1,568,000 | 1,695,000 | 1,086,000 | 1,278,000 | 1,243,000 | 741,000 | 1,071,000 | 1,082,323 | ||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2018 — 102,357 and 2017 — 72,420 | 383,147,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2018 — 49,136 and 2017 — 38,127 | 79,566,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
see notes to consolidated financial statements. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsdecember 31, 2018 and 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2018 and 2017; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive income | -2,033,000 | 924,000 | 2,066,000 | 5,606,000 | 1,534,000 | 893,000 | 260,000 | 100,000 | 133,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2018 — 2,011 and 2017 — 1,769 | 129,282,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2018 — 93,680 and 2017 — 72,420 | 224,540,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2018 — 46,088 and 2017 — 38,127 | 64,565,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiaries | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
consolidated balance sheets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
as of september 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2018 and december 31, 2017; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2018 — 1,921 and 2017 — 1,769 | 131,943,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2018 — 86,023 and 2017 — 72,420 | 232,880,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2018 — 43,246 and 2017 — 38,127 | 66,188,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsjune 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2018 and december 31, 2017; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2018 — 1,905 and 2017 — 1,769 | 119,146,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2018 — 78,573 and 2017 — 72,420 | 241,677,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2018 — 40,518 and 2017 — 38,127 | 66,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2018 and december 31, 2017; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2017 — 1,769 and 2016 — 1,587 | 105,536,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2017 — 72,420 and 2016 — 52,843 | 167,771,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2017 — 38,127 and 2016 — 30,048 | 59,553,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsdecember 31, 2017 and 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2017 and 2016; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2017 — 1,547 and 2016 — 1,587 | 101,394,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
employee receivables | 147,000 | 148,000 | 161,000 | 198,000 | 176,000 | 165,000 | 263,000 | 217,000 | -6,000 | 46,000 | 44,000 | 44,000 | 35,000 | -53,000 | -27,000 | -18,000 | -11,000 | -78,000 | -62,000 | 199,000 | 161,000 | 133,000 | 145,000 | 129,000 | 171,000 | 139,000 | 115,000 | 118,000 | 130,000 | 161,000 | 52,000 | 119,000 | 133,000 | 183,000 | 164,000 | 160,000 | 116,000 | 143,000 | 114,000 | |||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2017 — 67,320 and 2016 — 52,843 | 172,796,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2017 — 34,985 and 2016 — 30,048 | 55,707,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsas of september 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
advances from employees | 542,000 | 192,000 | 479,000 | 572,000 | 544,000 | 473,000 | 207,000 | 589,000 | 439,000 | 142,000 | 599,000 | 371,000 | 509,000 | -277,000 | 142,000 | 90,000 | 317,000 | 408,000 | -65,000 | 645,000 | 405,000 | 428,000 | 314,000 | 341,000 | 261,000 | 11,000 | 214,000 | 312,000 | 232,000 | 211,000 | 273,000 | 227,000 | 232,000 | 274,000 | 146,000 | 132,000 | 208,097 | |||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2017 and december 31, 2016; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2017 — 1,514 and 2016 — 1,587 | 103,689,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2017 — 62,108 and 2016 — 52,843 | 157,525,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2017 — 33,111 and 2016 — 30,048 | 53,681,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsas of june 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2017 and december 31, 2016; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2017 — 1,437 and 2016 — 1,587 | 95,252,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2017 — 57,373 and 2016 — 52,843 | 156,414,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2017 — 31,459 and 2016 — 30,048 | 52,176,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2017 and december 31, 2016; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2016 — 1,587 and 2015 — 1,297 | 80,521,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2016 — 52,843 and 2015 — 38,497 | 135,358,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2016 — 30,048 and 2015 — 26,603 | 47,339,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsdecember 31, 2016 and 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2016 and 2015; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2016 — 1,731 and 2015 — 1,297 | 79,697,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | 7,005,000 | 7,829,000 | 6,181,000 | 5,634,000 | -160,000 | -58,000 | -608,000 | -366,000 | -651,000 | -758,000 | -669,000 | -1,242,000 | 736,000 | -598,000 | -1,726,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2016 — 48,546 and 2015 — 38,497 | 139,613,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2016 — 28,441 and 2015 — 26,603 | 46,701,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsseptember 30, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of september 30, 2016 and december 31, 2015; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2016 — 1,498 and 2015 — 1,297 | 76,792,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2016 — 44,401 and 2015 — 38,497 | 76,111,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2016 — 28,569 and 2015 — 26,603 | 40,587,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsjune 30, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of june 30, 2016 and december 31, 2015; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2016 — 1,451 and 2015 — 1,297 | 71,574,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2016 — 41,290 and 2015 — 38,497 | 79,168,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2016 — 27,605 and 2015 — 26,603 | 40,641,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of march 31, 2016 and december 31, 2015; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables — net of allowance for uncollectible accounts — 2015 — 1,297 and 2014 — 893 | 70,292,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
developed technology — net of accumulated amortization — 2015 — 38,497 and 2014 — 27,982 | 69,861,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net of accumulated amortization — 2015 — 26,603 and 2014 — 22,480 | 39,493,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated balance sheetsdecember 31, 2015 and 2014 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock — 5,000 shares authorized as of december 31, 2015 and 2014; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net sales | 136,086,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | 4,818,000 | 5,174,000 | 22,974,000 | 14,303,000 | 6,539,000 | 2,823,000 | 16,570,000 | 4,423,000 | 671,000 | 19,710,000 | 19,069,000 | 23,044,000 | 22,530,000 | 15,588,000 | 12,301,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per common share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 110 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 110 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 9,068,000 | 35,929,000 | 26,719,000 | 17,593,000 | 8,702,000 | 32,542,000 | 15,729,000 | 7,683,000 | 22,534,000 | 16,724,000 | 19,194,000 | 12,271,000 | 9,444,000 | 8,275,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses on sales and/or abandonment of property and equipment | 37,000 | 916,000 | 549,000 | 91,000 | 177,000 | 204,000 | 31,000 | 271,000 | 317,000 | 242,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of patents and intangible assets | 14,000 | 1,427,000 | 1,360,000 | 34,000 | 8,208,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred credits | -43,000 | -175,000 | -131,000 | -88,000 | -45,000 | -139,000 | -64,000 | -32,000 | -174,000 | -140,000 | -106,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of long-term debt issuance costs | 247,000 | 987,000 | 741,000 | 494,000 | 247,000 | 845,000 | 399,000 | 199,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | 462,000 | 3,870,000 | -184,000 | 19,000 | 21,000 | 1,359,000 | -6,000 | 2,000 | 549,000 | 14,000 | 1,677,000 | 1,791,000 | 984,000 | 376,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefits from stock-based compensation | -860,000 | -576,000 | -243,000 | -236,000 | -168,000 | -259,000 | -124,000 | 53,000 | -877,000 | 716,000 | 3,122,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation expense | 520,000 | 1,460,000 | 1,004,000 | 663,000 | 339,000 | 1,467,000 | 783,000 | 459,000 | 1,917,000 | 1,454,000 | 1,644,000 | 1,182,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities, net of effects from acquisitions: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables | -2,334,000 | -13,599,000 | -9,198,000 | -7,152,000 | -4,115,000 | -6,445,000 | -5,190,000 | -1,473,000 | -6,576,000 | -7,521,000 | -3,323,000 | 57,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total adjustments | 14,098,000 | 30,351,000 | 17,282,000 | 13,600,000 | 5,137,000 | 34,803,000 | 9,942,000 | 2,222,000 | 27,228,000 | 13,093,000 | 10,971,000 | 7,540,000 | 16,531,000 | 6,805,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities | 19,272,000 | 53,325,000 | 31,585,000 | 20,139,000 | 7,960,000 | 51,373,000 | 14,365,000 | 2,893,000 | 46,938,000 | 32,162,000 | 34,015,000 | 30,070,000 | 32,119,000 | 19,106,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital expenditures for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property and equipment | -9,492,000 | -34,181,000 | -24,262,000 | -18,716,000 | -8,708,000 | -59,505,000 | -30,389,000 | -19,961,000 | -64,643,000 | -49,264,000 | -59,195,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets | -495,000 | -1,714,000 | -1,368,000 | -925,000 | -433,000 | -1,617,000 | -1,460,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale-leaseback transactions | 1,823,000 | 5,521,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of property and equipment | 3,000 | 98,000 | 62,000 | 21,000 | 18,000 | 113,000 | 53,000 | 8,000 | 43,000 | 9,000 | 5,000 | 27,000 | 11,000 | 27,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions, net of cash acquired | -1,250,000 | -5,927,000 | -4,202,000 | -1,450,000 | -31,600,000 | -192,762,000 | -10,250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities | -9,411,000 | -36,203,000 | -26,586,000 | -21,070,000 | -9,123,000 | -68,609,000 | -31,997,000 | -21,347,000 | -255,574,000 | -70,621,000 | -74,020,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2015 and 2014 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock | 4,021,000 | 8,146,000 | 3,811,000 | 3,528,000 | 803,000 | 3,729,000 | 876,000 | 571,000 | 3,755,000 | 3,326,000 | 95,454,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of long-term debt | 31,803,000 | 144,018,000 | 108,782,000 | 71,734,000 | 36,010,000 | 176,764,000 | 330,630,000 | 104,585,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments on long-term debt | -43,415,000 | -169,392,000 | -117,772,000 | -72,213,000 | -30,423,000 | -165,477,000 | -51,910,000 | -17,512,000 | -123,801,000 | -94,151,000 | -155,386,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contingent payments related to acquisitions | -166,000 | -67,000 | -55,000 | -38,000 | -24,000 | -77,000 | -38,000 | -19,000 | -57,000 | -36,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of taxes related to an exchange of common stock | -380,000 | -249,000 | -220,000 | -220,000 | -220,000 | -21,000 | -21,000 | -439,000 | -287,000 | -953,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from financing activities | -7,277,000 | -16,968,000 | -5,211,000 | 3,027,000 | 6,314,000 | 14,768,000 | 20,953,000 | 18,042,000 | 208,288,000 | 37,806,000 | 46,695,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates on cash | -31,000 | -258,000 | -809,000 | -154,000 | -19,000 | 208,000 | 103,000 | -290,000 | -61,000 | -10,000 | -297,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | 2,553,000 | 1,942,000 | 5,132,000 | -2,260,000 | 3,424,000 | -409,000 | -663,000 | 6,393,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
beginning of period | 7,355,000 | 7,459,000 | 7,459,000 | 7,459,000 | 9,719,000 | 9,719,000 | 10,128,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
end of period | 9,908,000 | 6,438,000 | 9,401,000 | 12,591,000 | 13,143,000 | 9,017,000 | 9,465,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the period for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | 1,254,000 | 9,014,000 | 7,204,000 | 4,969,000 | 2,644,000 | 7,877,000 | 2,970,000 | 1,493,000 | 434,000 | 238,000 | 509,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes | 931,000 | 3,289,000 | 2,679,000 | 1,911,000 | 782,000 | 735,000 | 1,071,000 | 403,000 | 5,277,000 | 4,629,000 | 7,023,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of non-cash investing and financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property and equipment purchases in accounts payable | 1,743,000 | 2,896,000 | 3,853,000 | 3,433,000 | 5,180,000 | 4,055,000 | 12,372,000 | 5,354,000 | 12,372,000 | 7,429,000 | 8,849,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (89 and 108 shares, respectively) in exchange for exercise of stock options | 1,725,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of cost-method investment | 2,368,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | 2,450,000 | 2,450,000 | 5,838,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
realized gain on sale of marketable securities | -745,000 | -745,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of marketable securities | 3,248,000 | 3,248,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2014, 2013 and 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from industrial assistant grants | 389,000 | 750,000 | 750,000 | 1,029,000 | 324,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt issuance costs | -798,000 | -3,706,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease) in cash and cash equivalents | -104,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
beginning of year | 7,459,000 | 9,719,000 | 10,128,000 | 3,735,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
end of year | 7,355,000 | 7,459,000 | 9,719,000 | 10,128,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the year for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable due for sale of equipment | 1,256,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of customer list in exchange for a settlement of trade receivables | 377,000 | 378,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition purchases in accrued expenses and other long-term obligations | 1,000,000 | 350,000 | 5,149,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options | 1,941,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale-leaseback transaction | 3,184,000 | 24,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2014 and 2013 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | -1,021,000 | -702,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options | 1,641,000 | 1,641,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses (gains) on sales and/or abandonment of property and equipment | 289,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of patents | 119,000 | 53,000 | 2,000 | 27,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2014 and 2013 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2014 and 2013 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (108 and 0 shares, respectively) in exchange for exercise of stock options | 1,641,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable securities | -2,503,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2013, 2012 and 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of offering costs related to issuance of common stock | -127,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options | 452,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sales and/or abandonment of property and equipment | -10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in fair value of contingent consideration liability related to acquisitions | 370,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax refund receivable | 1,073,000 | -782,000 | 452,000 | 259,000 | -733,000 | 319,000 | 28,227 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patents and trademarks | -661,000 | -394,000 | -1,059,000 | -2,077,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions | -1,000,000 | -1,000,000 | -23,555,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2013 and 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under long-term debt | 71,172,000 | 34,199,000 | 127,914,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of non-cash investing and financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (45 and 103 shares, respectively) in exchange for exercise of stock options | 452,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sales and/or abandonment of property and equipment | 7,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from stock-based compensation | -53,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2013 and 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of patents and license agreement | 55,000 | 103,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill impairment charge | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of trading investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unrealized gains on trading investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2012, 2011 and 2010 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings on line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments on line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (131, 78 and 0 shares, respectively) in exchange for exercise of stock options | 1,831,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(gain) loss on sales and/or abandonment of property and equipment | -1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit attributable to appreciation of common stock options exercised | -716,000 | -3,122,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2012 and 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (71 and 103 shares, respectively) in exchange for exercise of stock options | 1,032,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2011, 2010 and 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock repurchased and retired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition purchases in other long term obligations | 1,270,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (78, 0 and 27 shares, respectively) in exchange for exercise of stock options | 1,252,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 473 and 593, respectively | 40,579,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax refunds receivable | 467,000 | 472,000 | 428,000 | 177,000 | 267,000 | 667,000 | 651,000 | 626,000 | 1,108,000 | 350,000 | 418,000 | 105,000 | 188,000 | 81,000 | 19,000 | 46,000 | 22,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
building | 51,072,000 | 50,399,000 | 50,137,000 | 49,768,000 | 50,295,000 | 50,000,000 | 49,903,000 | 49,865,000 | 49,406,000 | 49,125,000 | 43,241,000 | 43,111,000 | 43,059,000 | 43,037,000 | 42,557,000 | 42,533,000 | 42,487,000 | 39,583,000 | 23,702,000 | 18,840,000 | 5,950,000 | 5,269,821 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property and equipment—net | 162,523,000 | 135,582,000 | 122,474,000 | 118,072,000 | 116,212,000 | 111,194,000 | 107,513,000 | 105,748,000 | 103,724,000 | 102,595,000 | 100,735,000 | 98,288,000 | 97,697,000 | 95,421,000 | 91,811,000 | 89,987,000 | 86,834,000 | 82,990,000 | 74,385,000 | 61,227,000 | 44,344,000 | 36,432,768 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangibles - net of accumulated amortization of 13,498 and 8,996, respectively | 58,544,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 492 and 593, respectively | 41,031,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangibles - net of accumulated amortization of 10,573 and 8,996, respectively | 56,828,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 660 and 541, respectively | 38,644,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 7,754 and 5,450, respectively | 59,796,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 599 and 541, respectively | 37,010,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 6,782 and 5,450, respectively | 26,958,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of june 30, 2010 and december 31, 2009; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 100,000 shares authorized; 28,205 and 28,181 shares issued at june 30, 2010 and december 31 2009, respectively | 64,724,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 487 and 541, respectively | 34,770,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangibles - net of accumulated amortization of 6,120 and 5,450, respectively | 27,294,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of certain patents and license agreement | 154,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of trading investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unrealized (gains) losses on trading investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities net of effects from acquisitions: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities related to unrecognized tax positions | 1,023,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-current liabilities related to unrecognized tax positions | 114,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 650 and 505, respectively | 31,812,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 4,720 and 3,122, respectively | 25,899,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deposits | 92,000 | 91,000 | 126,000 | 73,000 | 78,000 | 78,000 | 12,000 | 84,000 | 84,000 | 84,000 | 9,000 | 96,000 | 99,000 | 99,000 | 128,000 | 156,000 | 137,000 | 127,000 | 126,874 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other payables | 7,000,000 | 7,000,000 | 1,500,000 | 1,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities related to unrecognized tax positions | 2,681,000 | 2,818,000 | 2,818,000 | 2,588,000 | 2,588,000 | 3,388,000 | 3,857,000 | 3,692,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of september 30, 2009 and december 31, 2008; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 100,000 shares authorized; 28,059 and 28,093 shares issued at september 30, 2009 and december 31, 2008, respectively | 62,012,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 621 and 505, respectively | 30,454,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 3,986 and 3,122, respectively | 26,503,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of june 30, 2009 and december 31, 2008; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 100,000 shares authorized; 27,943 and 28,093 shares issued at june 30, 2009 and december 31 2008, respectively | 60,343,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 636 and 505, respectively | 29,794,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 3,421 and 3,122, respectively | 17,344,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of march 31, 2009 and december 31, 2008; no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 100,000 shares authorized; 27,916 and 28,093 shares issued at march 31, 2009 and december 31 2008, respectively | 59,732,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
marketable securities | 894,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 460 and 497, respectively | 26,330,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less accumulated depreciation and amortization | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 2,891 and 2,171, respectively | 6,998,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred compensation investments | 2,910,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 515 and 497, respectively | 25,212,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 2,671 and 2,171, respectively | 6,429,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred compensation assets | 3,053,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of june 30, 2008, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,635 and 27,413 shares issued at june 30, 2008 and december 31 2007, respectively | 55,272,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net of allowances of 511 and 497, respectively | 25,391,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - net of accumulated amortization of 2,396 and 2,171, respectively | 6,610,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term obligation | 389,000 | 178,000 | 62,000 | 75,000 | 87,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of march 31, 2008, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,589 and 27,413 shares issued at march 31, 2008 and december 31 2007, respectively | 54,564,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of assets | 929,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of certain patents and trademarks | 245,000 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 1,130,000 | 1,502,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash surrender value of life insurance contracts | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions—net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 530 and 560, respectively | 24,844,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 2,085 and 1,519, respectively | 6,438,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of september 30, 2007, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,304 and 27,647 shares issued at september 30, 2007 and december 31, 2006, respectively | 51,088,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 518 and 560, respectively | 25,029,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 1,897 and 1,519, respectively | 5,369,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of june 30, 2007, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,383 and 27,647 shares issued at june 30, 2007 and december 31, 2006, respectively | 51,755,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 544 and 560, respectively | 25,986,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 1,687 and 1,519, respectively | 4,705,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of march 31, 2007, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,711 and 27,647 shares issued at march 31, 2007 and december 31 2006, respectively | 55,336,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
note receivable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 498 and 767, respectively | 23,317,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 1,824 and 1,483, respectively | 4,298,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of september 30, 2006, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,399 and 27,163 shares issued at september 30, 2006 and december 31 2005, respectively | 51,707,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 442 and 767, respectively | 23,150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 1,634 | 3,595,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and 1,483, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
june 30, 2006, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized; 27,308 and 27,163 shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
at june 30, 2006 and december 31 2005, respectively | 50,179,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 400 and 767, respectively | 22,672,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 1,580 and 1,483, respectively | 3,320,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of march 31, 2006, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,217 and 27,163 shares issued at march 31, 2006 and december 31 2005, respectively | 49,163,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - net | 21,705,000 | 21,199,000 | 17,215,000 | 19,918,295 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles | 2,747,000 | 2,758,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other liabilities | 112,000 | 125,000 | 138,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of september 30, 2005, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 27,128 and 26,486 shares issued at september 30, 2005 and december 31 2004, respectively | 47,469,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of june 30, 2005, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 26,895 and 26,486 shares issued at june 30, 2005 and december 31 2004, respectively | 45,027,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables - less allowances of 735 and 758, respectively | 20,544,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
employee and other receivables | 203,000 | 157,000 | 339,287 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangibles - less accumulated amortization of 1,358 and 1,332, respectively | 2,767,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of march 31, 2005, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 26,515 and 26,486 shares issued at march 31, 2005 and december 31 2004, respectively | 42,887,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
land | 2,740,000 | 2,740,394 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
automobiles | 88,000 | 87,536 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patents, trademarks and licenses - net | 1,942,000 | 2,106,451 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred taxes payable | 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000 shares authorized as of june 30, 2004, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000 shares authorized; 26,429 and 26,003 shares issued at september 30, 2004 and december 31 2003, respectively | 41,676,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock—5,000,000 shares authorized as of june 30, 2004, no shares issued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value; 50,000,000 shares authorized; 26,334,864 and 26,002,544 shares issued at june 30, 2004 and december 31 2003, respectively | 40,678,352 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | 27,755,000 | 32,581,000 | 30,147,000 | 27,947,000 | 28,444,000 | 35,726,000 | 28,240,000 | 27,629,000 | 25,834,000 | 20,245,000 | 20,703,000 | 33,401,000 | 15,272,000 | 15,298,000 | 10,545,000 | 20,613,000 | 11,967,000 | 4,916,000 | 10,958,000 | 15,378,000 | -3,009,000 | -19,058,000 | -3,154,000 | -4,205,000 | -3,398,000 | 6,859,000 | 6,195,000 | 9,189,000 | 16,618,000 | 10,941,000 | 5,269,000 | 6,806,000 | -3,569,000 | 9,483,000 | 14,803,000 | 7,506,000 | 974,000 | 7,290,000 | 4,351,000 | 6,409,000 | 4,818,000 | 7,401,000 | 5,174,000 | 8,671,000 | 7,764,000 | 3,716,000 | 2,823,000 | 6,540,000 | 5,607,000 | 3,752,000 | 671,000 | 641,000 | 4,970,000 | 4,563,000 | 6,872,000 | 6,639,000 | 4,210,000 | -1,973,000 | 5,715,000 | 4,508,000 | 5,067,000 | 6,085,000 | 5,841,000 | 5,537,000 | 5,200,000 | 5,818,000 | 4,317,000 | 4,728,000 | 4,295,000 | 3,596,000 | 2,969,000 | 3,053,000 | 3,325,000 | 3,522,000 | 2,401,000 | 3,327,000 | 4,682,000 | 4,074,000 | 4,187,566 |
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 31,316,000 | 31,021,000 | 29,292,000 | 28,616,000 | 26,403,000 | 24,091,000 | 23,599,000 | 23,626,000 | 24,043,000 | 21,779,000 | 20,537,000 | 20,492,000 | 20,410,000 | 20,436,000 | 20,466,000 | 20,893,000 | 20,756,000 | 21,017,000 | 21,400,000 | 23,612,000 | 23,418,000 | 23,720,000 | 23,320,000 | 23,593,000 | 23,497,000 | 22,662,000 | 22,348,000 | 19,110,000 | 17,657,000 | 17,495,000 | 15,284,000 | 14,194,000 | 13,679,000 | 12,950,000 | 12,759,000 | 12,161,000 | 11,889,000 | 10,000,000 | 9,705,000 | 9,680,000 | 9,489,000 | 9,188,000 | 9,068,000 | 9,210,000 | 9,126,000 | 8,891,000 | 8,702,000 | 8,616,000 | 8,197,000 | 8,046,000 | 7,683,000 | 5,810,000 | 4,944,000 | 4,778,000 | 4,678,000 | 4,794,000 | 4,291,000 | 3,892,000 | 3,383,000 | 3,290,000 | 3,291,000 | 3,270,000 | 3,029,000 | 2,681,000 | 2,567,000 | 2,548,000 | 2,565,000 | 2,554,000 | 2,350,000 | 2,297,000 | 2,243,000 | 2,197,000 | 2,080,000 | 2,035,000 | 1,963,000 | 1,449,000 | 1,273,000 | 1,213,000 | 1,188,875 |
gain on disposition of business | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale or abandonment of property and equipment | 231,000 | 228,000 | 87,000 | 1,275,000 | 136,000 | 44,000 | 35,000 | 1,077,000 | 84,000 | 4,470,000 | 207,000 | 184,000 | 84,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of certain intangible assets and other long-term assets | 70,000 | 50,000 | 32,000 | 55,000 | 121,000 | 78,000 | 202,000 | 45,000 | 133,000 | 548,000 | 0 | 61,000 | 1,672,000 | 0 | 44,000 | 8,200,000 | 20,589,000 | 3,895,000 | 3,925,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of right-of-use operating lease assets | 2,927,000 | 2,782,000 | 2,984,000 | 2,980,000 | 2,980,000 | 2,941,000 | 3,122,000 | 2,686,000 | 2,686,000 | 3,273,000 | 2,662,000 | 2,575,000 | 2,698,000 | 2,537,000 | 2,584,000 | 2,777,000 | 2,867,000 | 3,004,000 | 3,070,000 | 3,224,000 | 3,183,000 | 3,205,000 | 3,134,000 | 3,030,000 | 3,352,000 | 2,910,000 | 2,964,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
fair value adjustments related to contingent consideration liabilities | 32,000 | 143,000 | 1,023,000 | 151,000 | 103,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred credits | -25,000 | -26,000 | -26,000 | -26,000 | -25,000 | -26,000 | -26,000 | -26,000 | -26,000 | -26,000 | -26,000 | -26,000 | -27,000 | -27,000 | -27,000 | -27,000 | -27,000 | -27,000 | -27,000 | -27,000 | -34,000 | -34,000 | -35,000 | -35,000 | -34,000 | -35,000 | -35,000 | -36,000 | -35,000 | -35,000 | -36,000 | -36,000 | -35,000 | -36,000 | -40,000 | -42,000 | -43,000 | -42,000 | -43,000 | -42,000 | -44,000 | -42,000 | -43,000 | -44,000 | -43,000 | -43,000 | -45,000 | -42,000 | -33,000 | -32,000 | -32,000 | -34,000 | -25,000 | ||||||||||||||||||||||||||
amortization and write-off of long-term debt issuance costs | 1,414,000 | 1,414,000 | 1,414,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation expense | 13,612,000 | 10,873,000 | 9,078,000 | 9,515,000 | 6,713,000 | 7,011,000 | 5,234,000 | 5,987,000 | 5,797,000 | 5,580,000 | 3,969,000 | 4,351,000 | 4,598,000 | 4,451,000 | 4,642,000 | 4,501,000 | 4,857,000 | 3,137,000 | 3,595,000 | 4,071,000 | 4,063,000 | 3,428,000 | 2,777,000 | 2,467,000 | 2,626,000 | 2,523,000 | 1,766,000 | 1,623,000 | 1,673,000 | 1,565,000 | 1,256,000 | 1,192,000 | 1,192,000 | 1,114,000 | 577,000 | 593,000 | 503,000 | 786,000 | 624,000 | 600,000 | 558,000 | 565,000 | 520,000 | 456,000 | 341,000 | 324,000 | 339,000 | 395,000 | 289,000 | 324,000 | 459,000 | 463,000 | |||||||||||||||||||||||||||
changes in operating assets and liabilities, net of acquisitions: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables | -6,346,000 | 250,000 | -7,560,000 | -4,146,000 | -2,639,000 | -2,719,000 | -4,182,000 | -8,064,000 | 2,128,000 | -1,100,000 | -4,880,000 | -6,053,000 | 409,000 | -5,621,000 | -3,851,000 | -2,438,000 | 1,653,000 | -2,549,000 | -5,284,000 | -2,624,000 | -2,243,000 | 11,847,000 | 3,445,000 | -11,114,000 | 14,420,000 | -9,649,000 | -11,557,000 | -2,040,000 | 2,465,000 | -14,781,000 | -13,166,000 | -1,881,000 | 2,285,000 | -7,491,000 | -5,757,000 | -1,650,000 | 1,293,000 | -5,624,000 | -835,000 | -2,348,000 | -731,000 | -459,000 | -2,334,000 | -4,401,000 | -2,046,000 | -3,037,000 | -4,115,000 | -2,745,000 | 1,490,000 | -3,717,000 | -1,473,000 | 945,000 | -132,000 | -1,545,000 | 159,000 | 1,505,000 | 308,000 | -2,129,000 | -314,000 | -313,000 | 2,813,000 | ||||||||||||||||||
other receivables | -701,000 | 3,101,000 | -284,000 | -1,812,000 | -4,171,000 | 206,000 | -705,000 | 3,469,000 | -1,327,000 | 1,752,000 | -1,465,000 | -1,515,000 | -788,000 | 603,000 | 5,854,000 | -7,245,000 | -2,380,000 | -196,000 | -597,000 | 498,000 | 527,000 | 30,000 | 613,000 | 1,787,000 | -355,000 | -643,000 | 1,070,000 | -3,009,000 | -711,000 | 68,000 | 898,000 | -3,054,000 | -335,000 | -542,000 | 374,000 | -2,239,000 | 1,259,000 | 759,000 | 1,367,000 | -389,000 | -166,000 | 1,677,000 | -735,000 | -2,157,000 | -132,000 | -1,192,000 | 439,000 | -174,000 | 28,000 | 123,000 | -586,000 | -270,000 | -41,000 | 17,000 | 173,000 | 171,000 | 8,000 | 266,000 | 78,000 | 54,000 | 124,000 | 253,000 | |||||||||||||||||
inventories | -3,353,000 | -1,121,000 | -10,599,000 | 557,000 | -5,963,000 | 3,501,000 | -382,000 | 2,321,000 | 1,076,000 | -12,528,000 | -22,974,000 | -17,194,000 | -15,969,000 | -5,589,000 | -9,177,000 | -14,003,000 | -14,365,000 | 6,581,000 | -3,396,000 | 13,761,000 | 13,413,000 | 7,238,000 | -4,983,000 | -7,742,000 | -14,164,000 | -3,798,000 | -1,340,000 | -8,797,000 | -12,186,000 | -1,801,000 | -5,388,000 | -7,912,000 | -7,762,000 | -3,004,000 | 844,000 | -3,876,000 | 1,623,000 | 869,000 | -2,272,000 | -5,681,000 | -7,598,000 | -3,352,000 | 3,518,000 | 1,157,000 | -6,459,000 | -1,742,000 | -2,352,000 | -827,000 | 122,000 | 890,000 | 2,149,000 | -81,000 | -3,354,000 | 245,000 | 353,000 | 2,634,000 | 1,426,000 | 588,000 | 408,000 | ||||||||||||||||||||
prepaid expenses and other current assets | -463,000 | -4,616,000 | 2,041,000 | 1,576,000 | -3,565,000 | -3,071,000 | 765,000 | 1,353,000 | -150,000 | -1,308,000 | 1,386,000 | 2,388,000 | -2,031,000 | -848,000 | -1,307,000 | 2,696,000 | -2,428,000 | -2,752,000 | -1,071,000 | 3,483,000 | -2,580,000 | 1,777,000 | -3,126,000 | 2,620,000 | -2,807,000 | -1,071,000 | 19,000 | 719,000 | 386,000 | -1,882,000 | -1,223,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
income tax refund receivables | 3,513,000 | -5,796,000 | 2,143,000 | 5,994,000 | -3,909,000 | -3,926,000 | 305,000 | 8,624,000 | -5,105,000 | -3,307,000 | -270,000 | 3,665,000 | -1,709,000 | -200,000 | 196,000 | -221,000 | 969,000 | -208,000 | 199,000 | 8,327,000 | -1,337,000 | -4,854,000 | -2,475,000 | 6,433,000 | -4,700,000 | -3,538,000 | -442,000 | 98,000 | 1,280,000 | -941,000 | -205,000 | -868,000 | -14,000 | 644,000 | -350,000 | -108,000 | -358,000 | 448,000 | 424,000 | -566,000 | -140,000 | 461,000 | -539,000 | 1,000 | -14,000 | -168,000 | 192,000 | 27,000 | |||||||||||||||||||||||||||||||
other assets | -358,000 | -1,295,000 | -176,000 | -2,206,000 | -892,000 | -21,000 | -2,947,000 | -5,257,000 | 839,000 | -1,479,000 | -79,000 | -1,191,000 | 80,000 | 935,000 | 833,000 | 1,968,000 | -2,953,000 | -765,000 | 80,000 | -2,423,000 | -1,216,000 | 705,000 | -577,000 | -1,309,000 | -987,000 | -753,000 | -2,092,000 | 1,685,000 | -619,000 | -260,000 | -491,000 | -743,000 | -1,492,000 | -328,000 | -1,172,000 | -2,172,000 | -829,000 | -871,000 | 109,000 | 414,000 | 2,111,000 | -2,285,000 | -602,000 | -260,000 | -487,000 | 206,000 | -847,000 | -883,000 | -110,000 | -436,000 | -377,000 | -309,000 | 22,000 | ||||||||||||||||||||||||||
trade payables | -269,000 | -756,000 | 4,453,000 | 4,175,000 | 607,000 | 7,052,000 | -14,148,000 | 13,035,000 | -13,079,000 | -4,290,000 | -2,963,000 | 2,909,000 | 6,039,000 | 1,043,000 | 2,670,000 | 4,869,000 | -4,458,000 | 1,402,000 | 4,237,000 | 3,015,000 | 1,190,000 | -8,212,000 | 4,340,000 | 1,480,000 | -5,113,000 | 2,216,000 | -878,000 | -210,000 | 169,000 | 7,358,000 | 8,409,000 | 1,293,000 | -4,540,000 | 2,625,000 | 1,039,000 | 2,183,000 | -3,871,000 | -7,547,000 | 2,400,000 | 5,028,000 | 4,516,000 | 5,138,000 | 84,000 | 4,671,000 | -1,644,000 | 2,784,000 | -485,000 | 4,073,000 | -4,664,000 | 2,670,000 | -2,084,000 | 1,916,000 | 1,892,000 | 5,326,000 | -28,000 | -2,806,000 | -407,000 | 1,728,000 | 1,781,000 | -829,000 | -91,000 | 1,392,000 | 220,000 | -286,000 | -166,000 | 537,000 | 1,448,000 | -1,552,000 | 1,630,000 | 127,180 | |||||||||
accrued expenses | 7,589,000 | 18,007,000 | -20,747,000 | 10,329,000 | 2,190,000 | 6,087,000 | -8,891,000 | -1,885,000 | 9,696,000 | -6,724,000 | -3,571,000 | -7,518,000 | 12,105,000 | 2,542,000 | -23,508,000 | 16,887,000 | 10,369,000 | 3,813,000 | 5,393,000 | -17,988,000 | 2,927,000 | 21,285,000 | -1,621,000 | 9,514,000 | -1,859,000 | 5,375,000 | -3,450,000 | 4,999,000 | 240,000 | 9,862,000 | -2,395,000 | 1,947,000 | -3,319,000 | 4,548,000 | 3,285,000 | 1,552,000 | -1,346,000 | 6,975,000 | -3,936,000 | -1,361,000 | 2,542,000 | 1,822,000 | 2,653,000 | 1,451,000 | 1,147,000 | 671,000 | 2,868,000 | -127,000 | 3,556,000 | -1,425,000 | -2,280,000 | 1,655,000 | -1,272,000 | 2,288,000 | 549,000 | 573,000 | -977,000 | 949,000 | 1,086,000 | 570,000 | 541,000 | 1,045,000 | 209,000 | -433,000 | 17,000 | 1,089,000 | 199,000 | -490,000 | |||||||||||
income taxes payable | 1,948,000 | -381,000 | 1,918,000 | 461,000 | 1,623,000 | -7,520,000 | 3,651,000 | 1,746,000 | 1,465,000 | -7,554,000 | 2,658,000 | 5,895,000 | -2,488,000 | -33,000 | 1,147,000 | 1,481,000 | -740,000 | -686,000 | -174,000 | -1,165,000 | -493,000 | -537,000 | 2,109,000 | 577,000 | 1,131,000 | -1,180,000 | -879,000 | 2,446,000 | 548,000 | -1,596,000 | -480,000 | 785,000 | -463,000 | -279,000 | -22,000 | 1,634,000 | -1,803,000 | 1,042,000 | 578,000 | -1,847,000 | 1,137,000 | 1,532,000 | 1,377,000 | -2,165,000 | 2,489,000 | 668,000 | 91,000 | 393,000 | 1,181,000 | -1,285,000 | -34,000 | -613,000 | -3,910,000 | 1,271,000 | 2,595,000 | 2,702,000 | -1,462,000 | 309,000 | 578,000 | 1,612,000 | -1,034,000 | -353,000 | 77,000 | 2,135,000 | 1,279,000 | -1,444,000 | 1,855,000 | 875,000 | -234,000 | -377,000 | 1,331,000 | 1,169,000 | 593,000 | 207,000 | 755,000 | 964,000 | -1,164,004 | ||
deferred compensation payable | -2,717,000 | 1,183,000 | -580,000 | -21,000 | 630,000 | 360,000 | 1,061,000 | 1,658,000 | -909,000 | 549,000 | 605,000 | 477,000 | -776,000 | -1,242,000 | -1,307,000 | 697,000 | 359,000 | 828,000 | -581,000 | 1,412,000 | 1,202,000 | 128,000 | -789,000 | 1,359,000 | 758,000 | 257,000 | 1,261,000 | -955,000 | 556,000 | 435,000 | 3,000 | 863,000 | 594,000 | 326,000 | 187,000 | 212,000 | -103,000 | 908,000 | -305,000 | -433,000 | -524,000 | 349,000 | 473,000 | 158,000 | 112,000 | 250,000 | 282,000 | 1,012,000 | 218,000 | 366,000 | 281,000 | 533,000 | 203,000 | -286,000 | 191,000 | 219,000 | 757,000 | 83,000 | -23,000 | 59,000 | 334,000 | 312,000 | 188,006 | ||||||||||||||||
operating lease liabilities | -2,653,000 | -2,590,000 | -3,335,000 | -3,127,000 | -3,094,000 | -3,031,000 | -2,931,000 | -2,919,000 | -2,862,000 | -3,474,000 | -2,237,000 | -2,721,000 | -2,797,000 | -2,768,000 | -2,841,000 | -3,045,000 | -3,106,000 | -3,108,000 | -3,151,000 | -3,261,000 | -3,221,000 | -3,232,000 | -2,945,000 | -3,014,000 | -3,074,000 | -2,828,000 | -3,054,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term obligations | 1,460,000 | -1,496,000 | -733,000 | -1,929,000 | 164,000 | -60,000 | 2,854,000 | -212,000 | -74,000 | -1,855,000 | -389,000 | 787,000 | -796,000 | -287,000 | 574,000 | -1,059,000 | -62,000 | 207,000 | 56,000 | -984,000 | 2,575,000 | 2,194,000 | -179,000 | -7,085,000 | 2,976,000 | 1,060,000 | 1,148,000 | 580,000 | -1,202,000 | 158,000 | -337,000 | 1,936,000 | -333,000 | 117,000 | 790,000 | 51,000 | -39,000 | -136,000 | -76,000 | 1,167,000 | -39,000 | 208,000 | 433,000 | -198,000 | 318,000 | 496,000 | -50,000 | -787,000 | -3,485,000 | -421,000 | 294,000 | -403,000 | -1,046,000 | 560,000 | 377,000 | 39,000 | 2,000 | ||||||||||||||||||||||
total adjustments | 47,227,000 | 50,726,000 | 10,425,000 | 40,797,000 | 18,889,000 | 32,780,000 | 7,976,000 | 34,622,000 | 25,235,000 | -2,959,000 | -6,158,000 | -5,393,000 | 20,217,000 | 23,486,000 | 1,465,000 | 25,202,000 | 13,009,000 | 36,292,000 | 24,274,000 | 21,537,000 | 58,148,000 | 63,410,000 | 32,018,000 | 31,114,000 | 18,612,000 | 15,326,000 | 7,310,000 | 14,487,000 | 11,190,000 | 16,173,000 | 2,666,000 | 12,528,000 | 12,396,000 | 9,905,000 | 375,000 | 9,755,000 | 9,920,000 | 6,571,000 | 7,232,000 | 6,044,000 | 11,805,000 | 13,709,000 | 14,098,000 | 13,069,000 | 3,682,000 | 8,463,000 | 5,137,000 | 11,209,000 | 13,652,000 | 7,720,000 | 2,222,000 | 14,135,000 | 337,000 | 10,538,000 | 9,929,000 | 7,733,000 | 4,076,000 | 562,000 | 1,499,000 | 244,000 | 1,986,000 | 3,811,000 | -2,050,000 | 438,000 | 5,286,000 | 5,485,000 | 4,175,000 | 4,046,000 | 2,825,000 | 1,306,000 | -91,000 | 639,000 | 4,951,000 | 1,001,000 | 3,164,670 | ||||
net cash, cash equivalents, and restricted cash from operating activities | 74,982,000 | 83,307,000 | 40,572,000 | 68,744,000 | 47,333,000 | 68,506,000 | 36,216,000 | 62,251,000 | 51,069,000 | 17,286,000 | 14,545,000 | 28,008,000 | 35,489,000 | 38,784,000 | 12,010,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from investing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital expenditures for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property and equipment | -22,440,000 | -13,751,000 | -21,061,000 | -3,472,000 | -9,359,000 | -10,627,000 | -11,682,000 | -7,139,000 | -8,595,000 | -5,771,000 | -12,785,000 | -12,490,000 | -15,776,000 | -7,237,000 | -9,526,000 | -8,327,000 | -6,795,000 | -6,646,000 | -6,171,000 | -10,398,000 | -9,787,000 | -11,853,000 | -13,950,000 | -20,069,000 | -22,145,000 | -17,704,000 | -18,255,000 | -16,300,000 | -15,465,000 | -15,320,000 | -16,239,000 | -9,101,000 | -11,740,000 | -7,604,000 | -10,178,000 | -6,345,000 | -5,270,000 | -10,231,000 | -10,991,000 | -11,458,000 | -14,135,000 | -15,874,000 | -9,492,000 | -9,919,000 | -5,546,000 | -10,008,000 | -8,708,000 | -11,470,000 | -17,646,000 | -10,428,000 | -19,961,000 | -15,379,000 | -22,109,000 | ||||||||||||||||||||||||||
intangible assets | -1,031,000 | -839,000 | -457,000 | -765,000 | -562,000 | -715,000 | -861,000 | -655,000 | -709,000 | -776,000 | -271,000 | -1,266,000 | -997,000 | -570,000 | -342,000 | -713,000 | -652,000 | -777,000 | -692,000 | -789,000 | -709,000 | -728,000 | -1,062,000 | -764,000 | -953,000 | -754,000 | -853,000 | -778,000 | -479,000 | -870,000 | -885,000 | -650,000 | -845,000 | -414,000 | -668,000 | -623,000 | -605,000 | -507,000 | -482,000 | -571,000 | -510,000 | -380,000 | -495,000 | -346,000 | -443,000 | -492,000 | -433,000 | ||||||||||||||||||||||||||||||||
proceeds from the sale of property and equipment | 4,000 | 0 | 3,000 | 20,000 | -20,000 | 1,000 | 200,000 | 2,000 | 4,000 | 0 | 153,000 | 11,000 | 873,000 | 9,000 | 6,000 | 658,000 | 240,000 | 19,000 | 3,000 | 48,000 | 3,000 | 1,000 | 3,000 | 12,000 | 6,000 | 0 | 3,000 | 14,000 | 1,205,000 | 36,000 | 3,000 | 3,000 | 36,000 | 41,000 | 3,000 | 18,000 | 41,000 | 19,000 | 45,000 | 8,000 | 34,000 | 0 | 1,000 | 6,000 | 3,000 | 7,000 | 4,000 | 8,000 | 1,000 | 12,000 | 0 | 1,287 | |||||||||||||||||||||||||||
proceeds from disposition of business | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for notes receivable and other investments | -319,000 | -7,500,000 | -7,117,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions, net of cash acquired | -279,000 | -121,555,000 | -1,000,000 | -3,346,000 | 0 | 71,000 | -136,349,000 | -2,000,000 | -3,575,000 | 0 | -5,313,000 | 0 | -1,500,000 | -358,000 | -10,693,000 | -160,000 | -392,000 | -16,256,000 | -35,314,000 | -1,942,000 | -179,019,000 | -4,116,000 | -18,459,000 | -100,195,000 | -2,082,000 | -48,691,000 | -7,348,000 | -47,461,000 | -5,353,000 | -97,008,000 | -1,300,000 | -21,500,000 | -500,000 | -9,618,000 | -1,000,000 | -1,250,000 | -1,725,000 | -2,752,000 | |||||||||||||||||||||||||||||||||||||||||
net cash, cash equivalents, and restricted cash from investing activities | -24,065,000 | -143,351,000 | -29,635,000 | -214,447,000 | -115,668,000 | -16,487,000 | -22,051,000 | -8,343,000 | -9,253,000 | -142,895,000 | -14,856,000 | -17,329,000 | -16,769,000 | -13,431,000 | -9,868,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
see condensed notes to consolidated financial statements. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock | 13,152,000 | 25,484,000 | 4,493,000 | 3,201,000 | 7,730,000 | 4,138,000 | 1,983,000 | 5,435,000 | 4,028,000 | 13,337,000 | 3,489,000 | 1,603,000 | 1,641,000 | 3,492,000 | 6,034,000 | 6,260,000 | 5,520,000 | 1,681,000 | 1,284,000 | 2,409,000 | 1,261,000 | 389,000 | 2,489,000 | 1,641,000 | 1,733,000 | 1,717,000 | 210,025,000 | 1,740,000 | 1,511,000 | 741,000 | 2,080,000 | 2,420,000 | 138,569,000 | 849,000 | 3,631,000 | 234,000 | 557,000 | 744,000 | 780,000 | 1,123,000 | 4,021,000 | 4,335,000 | 283,000 | 2,725,000 | 803,000 | 2,570,000 | 283,000 | 305,000 | 571,000 | 429,000 | 1,025,000 | 284,000 | 101,000 | 1,725,000 | 949,000 | ||||||||||||||||||||||||
payments on long-term debt | -23,000,000 | -52,000,000 | 0 | -24,063,000 | -188,000,000 | -73,153,000 | -268,419,000 | -50,052,000 | -61,550,000 | -74,030,000 | -53,664,000 | -70,899,000 | -61,045,000 | -54,341,000 | -50,966,000 | -40,569,000 | -28,694,000 | -60,614,000 | -43,152,000 | -24,540,000 | -52,682,000 | -28,731,000 | -66,627,000 | -54,119,000 | -72,033,000 | -264,748,000 | -36,856,000 | -148,971,000 | -45,252,000 | -18,603,000 | -8,636,000 | -170,723,000 | -19,440,000 | -12,971,000 | -35,311,000 | -34,376,000 | -45,095,000 | -44,121,000 | -36,641,000 | -43,415,000 | -51,620,000 | -45,559,000 | -41,790,000 | -30,423,000 | -68,843,000 | -44,724,000 | -34,398,000 | -17,512,000 | -29,650,000 | ||||||||||||||||||||||||||||||
contingent payments related to acquisitions | -52,000 | -52,000 | -67,000 | -64,000 | -78,000 | -67,000 | -68,000 | -866,000 | -2,568,000 | -56,000 | -64,000 | -8,307,000 | -24,491,000 | -86,000 | -10,090,000 | -86,000 | -403,000 | -109,000 | -130,000 | -107,000 | -12,754,000 | -56,000 | -15,073,000 | -57,000 | -554,000 | -47,000 | -54,000 | -115,000 | -15,000 | -16,000 | -15,000 | -15,000 | -15,000 | -19,000 | -16,000 | -16,000 | -167,000 | -1,018,000 | -14,000 | -14,000 | -166,000 | -12,000 | -17,000 | -14,000 | -24,000 | -17,000 | -22,000 | -19,000 | -19,000 | -21,000 | |||||||||||||||||||||||||||||
payment of taxes related to an exchange of common stock | -6,145,000 | 0 | 0 | 0 | -1,592,000 | 0 | -3,531,000 | 0 | -1,592,000 | -349,000 | -1,110,000 | 0 | -1,015,000 | 0 | -88,000 | 0 | -488,000 | 0 | 0 | 0 | -866,000 | 0 | 0 | 0 | -258,000 | -280,000 | -380,000 | -29,000 | 0 | 0 | -220,000 | 0 | 0 | -152,000 | |||||||||||||||||||||||||||||||||||||||||||||
net cash, cash equivalents, and restricted cash from financing activities | 6,955,000 | 2,432,000 | -47,574,000 | 3,137,000 | -18,003,000 | 472,810,000 | -54,553,000 | 141,506,000 | -497,000 | -5,749,000 | -27,067,000 | -13,204,000 | -14,240,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates on cash, cash equivalents, and restricted cash | 936,000 | -3,239,000 | 2,474,000 | -431,000 | -1,319,000 | 1,697,000 | -684,000 | -1,873,000 | 376,000 | 2,036,000 | -3,298,000 | -2,675,000 | 111,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | 18,828,000 | -146,510,000 | -113,435,000 | 528,415,000 | -13,421,000 | 6,966,000 | -11,645,000 | 9,474,000 | -11,987,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
beginning of period | 378,767,000 | 0 | 0 | 0 | 589,144,000 | 0 | 0 | 0 | 60,558,000 | 0 | 0 | 0 | 67,750,000 | 0 | 0 | 0 | 56,916,000 | 0 | 0 | 0 | 44,320,000 | 0 | 0 | 0 | 67,359,000 | 0 | 0 | 32,336,000 | 0 | 0 | 19,171,000 | 0 | 0 | 4,177,000 | 0 | 0 | 7,355,000 | 0 | 0 | 7,459,000 | 0 | 0 | 9,719,000 | 0 | 0 | 34,030,000 | 0 | 17,574,000 | 0 | 0 | 9,838,000 | 0 | 0 | 4,645,000 | 0 | 0 | 33,037,000 | -83 | |||||||||||||||||||||
end of period | 397,595,000 | -146,510,000 | -113,435,000 | 54,725,000 | 583,987,000 | 528,415,000 | -13,421,000 | 14,024,000 | 60,126,000 | 6,966,000 | -11,645,000 | 9,474,000 | 55,763,000 | -1,154,000 | -768,000 | 11,153,000 | 58,519,000 | 12,365,000 | -5,151,000 | -378,000 | 50,080,000 | 7,005,000 | 2,133,000 | -14,340,000 | 49,522,000 | 8,443,000 | 9,341,000 | 34,171,000 | -14,313,000 | 11,211,000 | 26,464,000 | 6,831,000 | 5,325,000 | 5,162,000 | -6,243,000 | 2,194,000 | 9,908,000 | -2,963,000 | -3,190,000 | 12,591,000 | -4,028,000 | 4,126,000 | 9,017,000 | 890,000 | -11,557,000 | 16,430,000 | 2,999,000 | 23,757,000 | 2,918,000 | -364,000 | 9,645,000 | -639,000 | -1,370,000 | 9,014,000 | -6,859,000 | -9,782,000 | 28,617,000 | -1,431,142 | |||||||||||||||||||||
reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 395,529,000 | -146,413,000 | -113,530,000 | 54,737,000 | 581,921,000 | 528,363,000 | -13,411,000 | 14,139,000 | 57,945,000 | 6,927,000 | -11,522,000 | 9,128,000 | 53,875,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash reported in prepaid expenses and other current assets | 2,066,000 | -97,000 | 95,000 | -12,000 | 2,066,000 | 52,000 | -10,000 | -115,000 | 2,181,000 | 39,000 | -123,000 | 346,000 | 1,888,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total cash, cash equivalents and restricted cash | 397,595,000 | -146,510,000 | -113,435,000 | 54,725,000 | 583,987,000 | 528,415,000 | -13,421,000 | 14,024,000 | 60,126,000 | 6,966,000 | -11,645,000 | 9,474,000 | 55,763,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the period for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | 12,361,000 | 2,267,000 | 16,573,000 | 2,011,000 | 2,393,000 | 4,479,000 | 5,891,000 | 1,679,000 | 2,002,000 | 2,171,000 | 1,770,000 | 1,324,000 | 993,000 | 1,106,000 | 1,232,000 | 1,384,000 | 1,539,000 | 1,939,000 | 2,201,000 | 2,739,000 | 3,198,000 | 3,115,000 | 3,525,000 | 3,073,000 | 2,721,000 | 2,306,000 | 2,304,000 | 3,331,000 | 2,383,000 | 1,754,000 | 1,567,000 | 1,643,000 | 2,743,000 | 2,649,000 | 3,311,000 | 1,534,000 | 1,378,000 | 1,560,000 | 1,434,000 | 2,025,000 | 1,254,000 | 1,810,000 | 2,235,000 | 2,325,000 | 2,644,000 | 2,496,000 | 2,411,000 | 1,477,000 | 1,493,000 | 196,000 | 29,000 | 9,000 | 2,000 | 3,000 | 2,000 | -1,000 | 1,000 | 3,000 | 2,000 | 3,000 | 2,000 | 13,000 | 0 | 5,000 | 363 | ||||||||||||||
income taxes | 3,784,000 | 11,993,000 | 10,435,000 | 20,553,000 | 2,066,000 | 6,659,000 | 7,088,000 | 15,320,000 | 2,467,000 | 3,079,000 | 6,150,000 | 5,452,000 | 2,411,000 | 2,662,000 | 1,555,000 | 2,951,000 | 1,660,000 | 2,469,000 | 2,641,000 | 2,171,000 | 1,637,000 | 1,998,000 | 1,215,000 | 6,922,000 | 1,934,000 | 2,623,000 | 928,000 | 3,331,000 | 1,810,000 | 2,020,000 | 1,351,000 | 1,107,000 | 1,571,000 | 81,000 | 657,000 | 1,152,000 | 428,000 | 504,000 | 696,000 | 1,278,000 | 931,000 | 610,000 | 768,000 | 1,129,000 | 782,000 | -1,289,000 | 953,000 | 668,000 | 403,000 | 648,000 | 2,854,000 | 3,063,000 | 463,000 | 4,733,000 | 2,876,000 | 1,668,000 | 1,634,000 | 218,000 | 1,555,000 | 1,428,000 | 36,000 | 1,260,000 | 2,427,000 | 1,221,000 | 2,179,248 | ||||||||||||||
supplemental disclosures of non-cash investing and financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property and equipment purchases in accounts payable | 3,813,000 | 4,337,000 | 3,496,000 | 248,000 | 5,163,000 | 3,654,000 | 322,000 | 704,000 | 3,587,000 | 1,803,000 | -1,656,000 | 1,113,000 | 2,442,000 | -284,000 | 1,828,000 | -674,000 | 1,688,000 | -546,000 | 756,000 | -3,413,000 | 5,383,000 | 471,000 | 4,150,000 | -1,257,000 | 4,588,000 | 1,931,000 | -885,000 | 2,191,000 | 1,752,000 | 598,000 | -166,000 | 804,000 | 756,000 | -311,000 | 1,212,000 | -87,000 | 1,584,000 | 878,000 | -31,000 | 609,000 | 1,743,000 | -957,000 | 420,000 | -1,747,000 | 5,180,000 | -1,285,000 | -7,032,000 | 7,018,000 | 5,354,000 | 4,943,000 | 118,000 | -113,000 | 1,689,000 | ||||||||||||||||||||||||||
acquisition purchases in accrued expenses and other long-term obligations | 4,020,000 | 62,000 | 341,000 | -1,864,000 | 6,417,000 | 39,000 | 39,000 | 8,052,000 | 958,000 | 1,183,000 | -1,512,000 | 6,000,000 | 0 | 149,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (18 and 0 shares, respectively) in exchange for exercise of stock options | 1,882,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
right-of-use operating lease assets obtained in exchange for operating lease liabilities | 24,871,000 | 756,000 | 1,024,000 | 408,000 | 7,759,000 | 1,331,000 | 4,161,000 | 3,312,000 | 87,000 | 2,182,000 | 4,202,000 | 3,342,000 | 1,404,000 | 697,000 | 466,000 | 230,000 | 131,000 | 3,653,000 | 256,000 | 4,229,000 | 2,800,000 | 3,206,000 | 4,504,000 | 1,765,000 | 1,162,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposition of business | 28,000 | 135,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | 0 | 0 | 0 | 0 | 0 | 0 | 500,000 | 25,000 | 262,000 | 76,000 | 0 | 12,061,000 | 61,000 | 300,000 | 0 | 0 | 2,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | -1,014,000 | 5,000 | 92,000 | -387,000 | -1,149,000 | 46,000 | -29,000 | 170,000 | 2,494,000 | 573,000 | -79,000 | 462,000 | 4,054,000 | -203,000 | -2,000 | 21,000 | 1,372,000 | -7,000 | -8,000 | 2,000 | 535,000 | 1,214,000 | 357,000 | 13,000 | 93,000 | 1,000 | 2,000 | -348,000 | 835,000 | 394,000 | 3,000 | 73,000 | |||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities, net of acquisitions and divestitures: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid income taxes | -68,000 | -127,000 | 8,000 | -53,000 | -324,000 | -20,000 | -28,000 | -72,000 | -380,000 | -139,000 | -3,000 | -89,000 | 467,000 | 55,000 | -80,000 | -38,000 | -1,745,000 | 0 | -95,000 | 52,000 | -74,000 | 30,000 | 35,000 | -25,000 | -9,000 | 17,000 | -369,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities related to unrecognized tax benefits | 963,000 | 1,240,000 | 768,000 | -580,000 | 383,000 | 784,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of long-term debt | 718,704,000 | 20,216,000 | 410,596,000 | 49,687,000 | 42,869,000 | 44,648,000 | 47,164,000 | 80,524,000 | 25,170,000 | 40,594,000 | 22,963,000 | 9,694,000 | 22,574,000 | 7,484,000 | 7,902,000 | 30,665,000 | 52,182,000 | 68,731,000 | 82,627,000 | 43,119,000 | 258,283,000 | 59,998,000 | 63,856,000 | 256,971,000 | 45,752,000 | 54,603,000 | 13,136,000 | 83,723,000 | 16,027,000 | 109,666,000 | 38,628,000 | 55,184,000 | 42,470,000 | 44,566,000 | 33,536,000 | 31,803,000 | 35,236,000 | 37,048,000 | 35,724,000 | 36,010,000 | |||||||||||||||||||||||||||||||||||||||
purchase of capped call option | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt issuance costs | 4,563,000 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0, 86, and 18 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of long-term debt issuance costs | 1,477,000 | 1,477,000 | 1,477,000 | 282,000 | 311,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 168,000 | 201,000 | 201,000 | 201,000 | 201,000 | 201,000 | 201,000 | 171,000 | 171,000 | 172,000 | 171,000 | 173,000 | 258,000 | 264,000 | 257,000 | 246,000 | 247,000 | 247,000 | 247,000 | 246,000 | 247,000 | 247,000 | 247,000 | 247,000 | 199,000 | 200,000 | 199,000 | |||||||||||||||||||||||||||||||||
issuance of note receivables | -500,000 | 0 | -6,162,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions and investments, net of cash acquired | -105,250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0 and 86 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments related to contingent consideration liabilities | -117,000 | 562,000 | 1,094,000 | 521,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -5,157,000 | -432,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash received for settlement of note receivable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of note receivable | -250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (86, 18 and 3 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments from disposition of business | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (86 and 15 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition purchases in other long-term obligations | 3,596,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current note receivable converted to equity investment | 0 | 0 | 0 | 899,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of business in other receivables | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (18, 3, and 39 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments and payments related to contingent consideration liability | 889,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (15 and 3 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0 and 2 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sales and/or abandonment of property and equipment | 94,000 | 673,000 | 388,000 | 270,000 | -28,000 | 856,000 | 933,000 | 333,000 | 37,000 | -522,000 | -166,000 | 515,000 | 288,000 | 54,000 | 20,000 | 351,000 | 7,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
fair value adjustments to contingent consideration | 2,600,000 | -161,000 | 1,115,000 | 1,805,000 | 402,000 | -8,844,000 | -4,356,000 | 343,000 | 4,897,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of business | -9,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term income taxes payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities | 45,815,000 | 24,976,000 | 41,208,000 | 35,232,000 | 36,915,000 | 55,139,000 | 44,352,000 | 28,864,000 | 26,909,000 | 15,214,000 | 22,185,000 | 13,505,000 | 23,676,000 | 27,808,000 | 27,114,000 | 7,935,000 | 19,334,000 | 8,827,000 | 19,388,000 | 15,178,000 | 17,261,000 | 10,894,000 | 13,861,000 | 11,583,000 | 12,453,000 | 16,623,000 | 21,110,000 | 19,272,000 | 21,740,000 | 11,446,000 | 12,179,000 | 7,960,000 | 17,749,000 | 19,259,000 | 11,472,000 | 2,893,000 | 14,776,000 | 5,307,000 | 15,101,000 | 9,004,000 | 4,603,000 | 14,139,000 | 5,760,000 | 9,791,000 | 5,070,000 | 6,566,000 | 6,329,000 | 3,150,000 | 6,256,000 | 9,603,000 | 10,213,000 | 8,470,000 | 7,642,000 | 5,794,000 | 4,359,000 | 3,234,000 | 4,161,000 | 7,352,000 | 5,075,000 | 7,352,236 | |||||||||||||||||||
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
free cash flows | 45,815,000 | 24,976,000 | 41,208,000 | 35,232,000 | 36,915,000 | 55,139,000 | 44,352,000 | 28,864,000 | 26,909,000 | 15,214,000 | 22,185,000 | 13,505,000 | 23,676,000 | 27,808,000 | 27,114,000 | 7,935,000 | 19,334,000 | 8,827,000 | 19,388,000 | 15,178,000 | 17,261,000 | 10,894,000 | 13,861,000 | 11,583,000 | 12,453,000 | 16,623,000 | 21,110,000 | 19,272,000 | 21,740,000 | 11,446,000 | 12,179,000 | 7,960,000 | 17,749,000 | 19,259,000 | 11,472,000 | 2,893,000 | 14,776,000 | 5,307,000 | 15,101,000 | 9,004,000 | 4,603,000 | 14,139,000 | 5,760,000 | 9,791,000 | 5,070,000 | 6,566,000 | 6,329,000 | 3,150,000 | 6,256,000 | 9,603,000 | 10,213,000 | 8,470,000 | 7,642,000 | 5,794,000 | 4,359,000 | 3,234,000 | 4,161,000 | 7,352,000 | 5,075,000 | 7,352,236 | |||||||||||||||||||
proceeds from sale of business | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities | -14,607,000 | -7,294,000 | -8,912,000 | -6,348,000 | -21,871,000 | -9,365,000 | -12,654,000 | -14,762,000 | -20,567,000 | -39,114,000 | -53,753,000 | -21,047,000 | -196,049,000 | -20,307,000 | -45,148,000 | -117,316,000 | -11,821,000 | -61,270,000 | -15,366,000 | -58,304,000 | -12,307,000 | -102,878,000 | -12,038,000 | -31,884,000 | -11,324,000 | -24,227,000 | -17,057,000 | -9,411,000 | -9,617,000 | -5,516,000 | -11,947,000 | -9,123,000 | -18,503,000 | -18,109,000 | -10,650,000 | -21,347,000 | -184,953,000 | -26,921,000 | |||||||||||||||||||||||||||||||||||||||||
net cash from financing activities | -32,469,000 | -17,891,000 | -21,829,000 | -26,246,000 | -4,548,000 | -51,976,000 | -32,948,000 | -6,234,000 | -167,000 | 25,937,000 | 17,584,000 | -9,821,000 | 187,920,000 | 2,239,000 | 28,625,000 | 109,496,000 | 809,000 | 38,064,000 | 6,923,000 | 50,721,000 | -2,441,000 | 98,815,000 | 3,526,000 | 21,195,000 | -2,747,000 | 1,504,000 | -1,715,000 | -7,277,000 | -11,757,000 | -8,238,000 | -3,287,000 | 6,314,000 | -946,000 | -5,239,000 | 2,911,000 | 18,042,000 | 170,482,000 | 1,973,000 | 877,000 | 1,104,000 | 640,000 | 800,000 | 1,892,000 | 1,117,000 | 506,000 | 455,786 | |||||||||||||||||||||||||||||||||
effect of exchange rates on cash | 107,000 | -559,000 | 686,000 | -1,035,000 | 1,869,000 | 1,051,000 | 872,000 | -2,108,000 | 830,000 | 96,000 | -356,000 | -474,000 | -143,000 | -1,297,000 | -1,250,000 | 1,720,000 | 652,000 | 66,000 | 266,000 | -302,000 | -660,000 | 0 | -24,000 | 91,000 | -64,000 | -143,000 | -144,000 | -31,000 | 551,000 | -655,000 | -135,000 | -19,000 | 44,000 | 61,000 | 393,000 | -290,000 | -51,000 | 207,000 | 158,000 | 184,000 | 22,000 | 86,000 | 1,000 | 119,000 | 11,000 | ||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -1,154,000 | -768,000 | 11,153,000 | 1,603,000 | 12,365,000 | -5,151,000 | -378,000 | 5,760,000 | 7,005,000 | 2,133,000 | -14,340,000 | -17,837,000 | 15,404,000 | 8,443,000 | 9,341,000 | 1,835,000 | 8,974,000 | -14,313,000 | 11,211,000 | 7,293,000 | 1,853,000 | 6,831,000 | 5,325,000 | 985,000 | 2,194,000 | 2,553,000 | -3,190,000 | 5,132,000 | 254,000 | 4,369,000 | -1,431,059 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (3, 39 and 3 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash received for settlement of current note receivable | 0 | 0 | 0 | 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (3 and 39 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (2 and 39 shares, respectively) in exchange for exercise of stock options | 0 | 93,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
offering costs | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (39, 3 and 43 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (39 and 3 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities, net of effects from acquisitions: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (39 and 0 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on bargain purchase | -243,000 | 778,000 | 669,000 | -12,243,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable for issuance of common stock associated with option exercises | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (3, 43, and 0 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of patents and intangible assets | 2,898,000 | 70,000 | 658,000 | 29,000 | 57,000 | 902,000 | 67,000 | 1,000 | 18,000 | 11,000 | 0 | 42,000 | 85,000 | 0 | 14,000 | 67,000 | 34,000 | 39,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (3 and 43 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2019 and 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0 and 32 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2019 and 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses on sales and/or abandonment of property and equipment | 208,000 | -15,000 | 22,000 | 212,000 | 428,000 | 58,000 | 15,000 | 29,000 | -144,000 | 68,000 | 16,000 | 37,000 | 367,000 | 91,000 | 28,000 | -1,000 | 0 | 4,000 | 84,000 | 169,000 | 172,000 | 108,000 | 54,000 | 16,000 | -4,000 | 205,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefits from stock-based compensation | -142,000 | -539,000 | 9,000 | 3,000 | -152,000 | -552,000 | -560,000 | -860,000 | -333,000 | -7,000 | -68,000 | -168,000 | -114,000 | -21,000 | -177,000 | 53,000 | -1,593,000 | 339,000 | 50,000 | 372,000 | 47,000 | 263,000 | 38,000 | 46,000 | 132,000 | 147,000 | 192,000 | 169,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of cost method investment | 0 | 0 | 0 | 1,089,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of notes receivable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
see notes to consolidated financial statements. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2018, 2017 and 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the year for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contingent receivable in exchange for sale of equity investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (43, 0 and 14 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiaries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
consolidated statements of cash flows | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
for the nine months ended september 30, 2018 and 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (43 and 0 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2018 and 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (32 and 0 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2018 and 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale-leaseback transactions | 0 | 0 | 194,000 | 1,823,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2017, 2016 and 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost method investment converted to intangible asset in acquisition in lieu of additional cash payment | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contingent receivable in exchange for sale of cost method investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0, 14 and 185 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
fair value changes in contingent liabilities/assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
employee receivables | 0 | 18,000 | 36,000 | -27,000 | -9,000 | 94,000 | -43,000 | -15,000 | -57,000 | 26,000 | -6,000 | 2,000 | 0 | 9,000 | 35,000 | 25,000 | -51,000 | -9,000 | -18,000 | 67,000 | 26,000 | 22,000 | 11,000 | 8,000 | 3,000 | -22,000 | 16,000 | 47,000 | 11,000 | 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | -357,000 | -1,459,000 | 229,000 | 42,000 | 233,000 | 57,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
advances from employees | 368,000 | -326,000 | -86,000 | 47,000 | 69,000 | 269,000 | -388,000 | 53,000 | -98,000 | -177,000 | 439,000 | -457,000 | 228,000 | -138,000 | 509,000 | -441,000 | 22,000 | 52,000 | 90,000 | -91,000 | -566,000 | 15,000 | -12,000 | -343,000 | -109,000 | 563,000 | -23,000 | 105,000 | 105,000 | 71,000 | -42,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2017 and 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of offering costs related to issuance of common stock | -1,000 | 18,000 | -833,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0 and 14 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2017 and 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2017 and 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | 723,000 | 1,774,000 | -1,728,000 | -498,000 | -197,000 | 132,000 | -471,000 | -160,000 | 550,000 | -242,000 | 285,000 | -651,000 | -56,000 | -33,000 | 573,000 | -1,242,000 | 1,334,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2016, 2015 and 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable due for sale of equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (14, 185 and 127 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2016 and 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of non-cash investing and financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contingent receivable received in exchange for sale of cost method investment | 30,000 | 0 | 681,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (14 and 185 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2016 and 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition purchases in accrued expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0 and 166 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2016 and 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (0 and 89 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2015, 2014 and 2013 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from industrial assistant grants | -511,000 | 150,000 | 0 | 750,000 | 705,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | -1,682,000 | -702,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (185, 127 and 45 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2015 and 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (185 and 108 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2015 and 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (166 and 108 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2015 and 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (89 and 108 shares, respectively) in exchange for exercise of stock options | 1,725,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of cost-method investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
realized gain on sale of marketable securities | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of marketable securities | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2014, 2013 and 2012 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease) in cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of customer list in exchange for a settlement of trade receivables | -1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale-leaseback transaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2014 and 2013 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses (gains) on sales and/or abandonment of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of patents | 51,000 | 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2014 and 2013 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2014 and 2013 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (108 and 0 shares, respectively) in exchange for exercise of stock options | 1,641,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2013, 2012 and 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sales and/or abandonment of property and equipment | 112,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax refund receivable | -546,000 | 1,855,000 | -782,000 | 193,000 | 103,000 | 16,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patents and trademarks | -482,000 | -267,000 | -394,000 | -309,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions | 0 | 0 | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2013 and 2012 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under long-term debt | 39,053,000 | 36,973,000 | 34,199,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of non-cash investing and financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (45 and 71 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in fair value of contingent consideration liability related to acquisitions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2013 and 2012 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (45 and 103 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from stock-based compensation | -53,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2013 and 2012 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of patents and license agreement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill impairment charge | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unrealized gains on trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2012, 2011 and 2010 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings on line of credit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments on line of credit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (131, 78 and 0 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(gain) loss on sales and/or abandonment of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit attributable to appreciation of common stock options exercised | -265,000 | 693,000 | 536,186 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2012 and 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (71 and 103 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2011, 2010 and 2009 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock repurchased and retired | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition purchases in other long term obligations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merit common stock surrendered (78, 0 and 27 shares, respectively) in exchange for exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of certain patents and trademarks | 42,000 | 3,000 | 14,000 | 84,000 | 0 | 24,000 | 27,000 | 40,000 | 150,000 | 60,000 | 0 | 0 | 0 | 40,000 | 36,000 | 15,000 | 14,000 | 209,507 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of goodwill | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net unrealized losses on trading investments | 237,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 436,000 | 311,000 | 335,000 | 344,000 | 302,000 | 304,000 | 305,000 | 277,000 | 298,000 | 293,000 | 239,000 | 98,000 | 371,000 | 363,000 | 249,000 | 147,000 | 306,000 | 432,000 | 374,000 | 390,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax refunds receivable | 3,000 | 955,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities related to unrecognized tax positions | 166,000 | 163,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of marketable securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net unrealized gains on trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of certain patents and license agreement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unrealized (gains) losses on trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities related to unrecognized tax benefits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-current liabilities related to unrecognized tax benefits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net unrealized losses (gains) on trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities net of effects from acquisitions: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deposits | 6,000 | 0 | 0 | 6,000 | 7,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit attritutable to appreciation of common stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
additions to long-term debt | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information—cash paid during the period for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net unrealized (gains)/losses on trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit attributable to appreciation of common stock options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of trading investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities related to unrecognized tax positions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-current liabilities related to unrecognized tax positions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of a certain patent and trademarks | 86,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable securities available for sale | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment on long-term debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued purchase price | 533,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease)/increase in cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by operating activities | 9,348,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sales of property and equipment | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash (used in) provided by financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cashflow information—cash paid during the period for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses on sales and/or abandonment of equipment | 332,000 | 205,000 | 4,000 | 182,000 | 0 | 70,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of certain patents and a license agreement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sale (purchase) of trading investment securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax benefit of options exercised | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of equipment | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of a certain patent and license agreement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in deferred compensation assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock | 134,000 | 329,000 | 664,000 | 407,000 | 1,749,000 | 973,000 | 292,000 | 462,091 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in deferred compensation payable | -129,000 | 72,000 | 81,000 | 7,000 | -1,000 | 224,000 | 147,000 | 146,000 | 216,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from (used by) financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase/(decrease) in cash and cash equivalents | 2,999,000 | 6,183,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease/(increase) in cash surrender value of life insurance contracts | 52,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sales of equipment | 2,000 | 5,000 | 8,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(decrease)/increase in deferred compensation payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adoption of fin 48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash surrender value of life insurance contracts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisitions—net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other liabilities | -12,000 | -12,000 | 137,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
principal payments on long-term debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash (used by) provided by financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net(decrease)/increase in cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
note receivable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses on sales and/or disposals of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bad debt expense | 57,000 | 0 | 24,000 | 11,000 | -8,000 | 32,000 | 16,063 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefits for stock-based compensation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provided by operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses (gains) on sales of property and equipment | -279 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net of effects from acquisitions: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
flow information—cash paid during | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
the period for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses on sales and abandonment of equipment | 29,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities net of effects from acquisition: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term obligation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid in acquisition | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
losses on sales of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net of effects from acquisition: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: net of effects from acquisition: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred credits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit attributable to appreciation of | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock options exercised | 36,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
employee and other receivables |